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Chapter 1 
 
 
Introduction 

Expression analysis of stress-induced apoptosis 
pathway regulating genes in B-cell lymphomas 
 
 
1 General introduction 
 
Lymphomas are tumours of malignant lymphocytes. Generally it is believed that at a 
certain point during development into a mature lymphocyte an event occurs resulting 
in a genetic defect. Lymphocyte development is a complex process, numerous 
subgroups of lymphocytes can be distinguished each resembling a certain stage in 
development. Lymphomas arise from lymphocytes within a certain stage of 
development, therefore lymphomas form an extremely heterogeneous group of 
malignancies. Lymphomas differ not only in microscopical appearance but also in 
clinical presentation. While some types of lymphomas respond extremely well to 
treatment, other lymphoma types offer a poor chance of survival.1 
Since lymphomas are tumors formed by malignant counterparts of lymphocytes it is 
important to understand how these normal lymphocytes function. By studying and 
comparing processes occurring in normal B-cells and their malignant counterparts, 
important genes in lymphoma development can be identified. These processes could 
involve the hallmarks of cancer such as self-sufficiency in growth signals, insensitivity 
to anti-growth signals, evading apoptosis and limitless replicative potential.2 The 
advent of micro array has greatly enhanced our ability to study gene expression 
profiles of various cell types, thereby facilitating research on pathways disrupted 
(either enhanced or inhibited) in malignancies. By stratifying patient groups based on 
these gene expression profiles and correlating these with survival data, important 
pathways in disease progression can be identified. In the long term, prognostic 
factors identified within patient groups with poor prognosis can possibly be used as 
drug targets. 
We studied expression levels of genes involved in regulation of apoptosis in diffuse 
large B-cell lymphomas.3 We believe that altered expression levels of these genes 
result in reduced sensitivity of these lymphomas to chemotherapy. Therefore 
expression levels of these genes can give clues on the genetic background of these 
lymphomas and can be of value in predicting disease outcome. 
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2 Normal B-cells 
 
Normal B-cells are an important part of the immune system. B-cells arise in the bone-
marrow from stem cells and differentiate through a complicated and highly regulated 
process into cells that can produce antibodies capable of recognizing specific foreign 
antigens. Further differentiation occurs in peripheral lymphoid organs after 
encountering specific antigens and involves fine tuning of the antigen recognition 
receptors in germinal centers.4 
 
 
2.1 Bone marrow 
 
Hematopoiesis primarily takes place in the bone marrow.5 Here pluripotent stem cells 
reside and give rise to the various types of blood cells.6,7,8 Pluripotent stem cells 
maintain, in contrast to differentiated blood cells, their proliferative ability throughout 
the life of an individual. Thus, in the bone marrow a pool of pluripotent stem cells is 
constantly present, renewing itself and giving rise to progenitor cells which will 
differentiate into the various types of blood cells. Roughly two lineages can be 
discriminated: the myeloid and the lymphoid lineage.5 
The lymphoid lineage arises from a distinct pool of progenitor cells and most are 
involved in the acquired immune response. Lymphocytes can be divided into a T and 
a B lymphocyte lineage. B cells arise and undergo their first maturation steps in the 
bone marrow, after leaving the bone marrow B cells can undergo further maturation 
in germinal centers in peripheral lymphoid organs while T cells mature in the thymus. 
Lymphoid cells are the only cells in the human body which undergo somatic 
mutations on purpose. These somatic mutations are located in the genomic area 
which encodes for the antigen recognition receptors, thus giving rise to a sheer 
infinite variety of antigens lymphocytes are able to recognize. 
The B-cell receptor (BCR) is formed by the joining of V, D and J regions, of each 
several copy numbers are present on each allele and only one copy of each V, D or J 
segment will eventually be present in the BCR. B-cells can only leave the bone 
marrow when a functional BCR is present on its surface which does not recognize 
self-antigens.4 
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2.2 Germinal center reaction 
 
After their first differentiation steps in the bone marrow, B-cells enter the bloodstream 
and migrate into peripheral lymphoid organs (lymph nodes).9 In these lymph nodes 
dendritic cells are present that have taken up foreign antigen, which is presented on 
their membrane. B-cells monitor the antigens present on the dendritic cells and upon 
recognition of the antigen by their BCR the germinal center reaction is initiated.10 
During the germinal center reaction the activated B-cells start to divide forming a 
secondary follicle. In a process called somatic hypermutation (SHM) small changes 
are introduced in the genomic area coding for the BCR. Because of these changes a 
wide variety of B-cells is made, all recognizing the same epitope but all with a 
different affinity. Only B-cells with a high affinity for the epitope and not recognizing 
any self-antigens receive a signal which allows them to fully mature. B-cells 
producing a BCR with lower affinity than the original B-cell or recognizing self-antigen 
will not receive a survival signal and will automatically go into apoptosis.11 Depending 
on the antigen the B-cell response is against, the BCR gets another constant region 
in a process called class switch recombination.12 This results in the recruitment of 
cells from the immune system which are best equipped to tackle the specific immune 
response. 
 
 
2.3 Mature B-cells 
 
Mature B-cells can migrate to the periphery where they produce antibodies 
recognizing the foreign antigen, thus inducing an immune response to remove the 
antigen. These mature B-cells are called plasma cells.13,14 The strength of a B-cell 
response to a certain antigen, however, does not lie in its short response-time. In 
fact, before B-cells are able to respond to a certain antigen several days have 
passed.4 For a fast response the innate immune response to an unknown antigen is 
much more suitable. The usefulness of the B-cells response lies in the fact that B-
cells produced against a specific antigen remain present in the body, these B-cells 
are called memory cells. Upon a renewed encounter with the specific antigen, a B-
cell mediated response by the memory B-cells is initiated rapidly.4 
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3 B-cell lymphomas 
 
The life-cycle of normal B-cells is strictly regulated. When something goes wrong in 
the mechanisms regulating cell-division, uncontrolled growth of B-cells can occur, 
resulting in induction of lymphoma. Lymphomas stem from uncontrolled growth of 
mature lymphocytes during or after the germinal centre reaction in lymph nodes. 
The cause of malignant transformation is often unknown but translocations and viral 
infections have been shown to play an important role in some types of lymphomas.15 
 
3.1 Hodgkin’s lymphoma 
 
Hodgkin’s lymphoma (HL) was first identified by Thomas Hodgkin16 and is a 
malignant proliferation of mature lymphocytes characterized by the presence of low 
numbers of neoplastic cells surrounded by high numbers of reactive T and B 
lymphocytes, histiocytes, and eosinophils.17 The neoplastic cells in HL are the Reed-
Sternberg (RS) cells and their mononuclear variants, the Hodgkin (H) cell.18,19 The 
large majority of classical H/RS cells have been shown to be clonal expansions 
originating from germinal center B cells.20 The exact mechanism responsible for 
malignant transformation and subsequent development of HL is unclear. Various 
mechanisms might be involved, including aberrant expression of tumor necrosis 
factor family members, infection with Epstein-Barr virus, and deregulation of the 
apoptosis pathway.15 
 
 
3.2 Non-Hodgkin B-cell lymphoma 
 
All B-cell lymphomas not belonging to the HL entity are designated non-Hodgkin 
lymphoma (NHL) which is an extremely heterogeneous group. Lymphomas present 
with widely variable appearances: size of lymphoma cells, infiltrating lymphocytes, 
site of presentation. Approximately 60% of primary NHL grow within lymph nodes 
(nodal) while the rest have an extranodal origin.1 Extranodal B cell lymphomas are 
originating in decreasing order in Gastro-intestinal tract, skin and pharynx (Waldeyers 
ring).21 
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Diffuse large B-cell lymphoma (DLBCL) and cutaneous large B-cell lymphoma 
(PCLBCL) are genetically related types of lymphomas. Major difference between 
these tumor types is the site of origin of the primary tumor, their properties will be 
discussed in detail below. 
 
 
3.2.1 Primary nodal DLBCL 
 
Diffuse large B-cell lymphomas (DLBCL) account for 40% of adult Non-Hodgkin 
lymphomas. At present the standard therapy for DLBCL is intensive combination 
chemotherapy cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone 
(CHOP) combined with Rituximab.22 Although this therapy cures a considerable 
number of DLBCL patients, the disease remains eventually fatal in 30–40% of cases. 
Fatal outcome usually results from failure to achieve complete remission or the 
occurrence of an early relapse. 
Micro-array analysis is a powerful tool to determine the expression of a great number 
of genes in one experiment. Because the expression of so many genes can be 
assessed at the same time, not only the expression of single genes but also the 
activity of complete pathways can be analyzed. 
In 2000 the first study on micro-array analysis of DLBCL was published by Alizadeh 
et al. 23 This and following studies using genome-wide micro array expression 
profiling demonstrated that DLBCL can be categorized into two major subtypes: one 
resembling germinal centre B-lymphocytes (GCB), the other resembling in vitro 
activated B-cells (ABC).23,24,25 The ABC-like DLBCL cases had a significantly worse 
prognosis than the GCB-like DLBCL cases with a 5-year survival of 16% and 76% 
respectively.23 Shipp et al. identified a third group within their DLBCL patients but 
their clustering method did not reveal statistically significant differences in 
prognosis.25   
Immunohistochemical analysis confirmed the clinical value of these subtypes.26,27 
Using only a small selection of markers identified in micro-array analysis ABC and 
GCB like DLBCL could be distinghuished. ABC-like DLBCL are characterized by 
constitutive activation of the nuclear factor B (NFB) pathway, resulting in up 
regulation of many genes including apoptosis-inhibiting genes. It is thought that this 
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NFB-mediated up regulation of anti-apoptotic genes causes intrinsic cellular 
resistance to chemotherapy,28 which would explain the poor outcome in patients with 
ABC-like DLBCL. 
 
 
3.2.2 Extra nodal B-cell lymphoma: PCBCL 
 
Primary cutaneous B-cell lymphomas (PCBCL) are a group of B-cell malignancies 
that arise in the skin and present without evidence for extra-cutaneous involvement at 
time of diagnosis. PCBCL can be divided into three entities, based upon histology 
and immunohistochemistry: primary cutaneous marginal zone B-cell lymphoma 
(PCMZL), primary cutaneous follicle center lymphomas (PCFCL) and primary 
cutaneous large B-cell lymphoma, leg type (PCLBCL, LT). PCLBCL, LT, with tumor 
localization mostly restricted to the legs, consists predominantly of tumor cells with 
round nuclei, while the tumor cells in PCFCL, with tumors localized primarily on trunk 
and scalp, resemble large centrocytes.1,29,30 
Patients presenting with PCLBCL, LT have a significantly poorer prognosis than 
those with PCFCL, with 5-year survival of about 50% and over 95% respectively. 
PCLBCL, LT patients are therefore treated with aggressive systemic (R-)CHOP 
chemotherapy while PCFCL patients receive local radiotherapy.29 
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4 Identification of pathogenic mechanisms related to poor 
response to therapy 
 
Several mechanisms have been found to be involved in the emergence of malignant 
lesions and subsequent prognosis. Malignant transformation relies on the 
accumulation of mutations causing limitless growth potential. Proliferation occurs 
without the need of stimulatory signals and is unaffected by inhibitory signals. Poor 
prognosis in various cancer types is linked to multi-drug resistance caused by the 
presence of ABC-transporter proteins which are capable of pumping drugs out of the 
cell.2 In DLBCL the expression of apoptosis inhibiting but, surprisingly, also inducing 
factors is correlated with poor response to therapy.31,32,33 By comparing gene 
expression patterns of neoplastic cells versus healthy cells clues can be obtained on 
causes of malignant transformation. The identification of factors responsible for poor 
prognosis is important in several aspects. Gene expression analysis in relation to 
clinical behaviour in tumor samples may help physicians to assess the prognosis and 
the clinical response to therapy of a patient.  In a broader sense, identification of 
gene expression signatures may help in finding pathways up- or down regulated in 
malignancies and thus point towards potential therapeutic targets.  
 
 
4.1 Apoptosis 
 
Apoptosis is a suicide mechanism present in every cell. In general apoptosis serves 
to get rid of unneeded or potentially dangerous cells.34,35,36 In B-lymphocytes 
apoptosis is important to prevent auto-reactive lymphocytes from developing and 
proliferating during the germinal center reaction.37,38 
Several routes can lead to apoptotic cell death.39,40,41,42 The extrinsic route is induced 
by binding of ligands to death receptors on the cell surface of the target cell. Upon 
binding an intracellular, caspase 8 dependent, pathway is initiated leading to 
cleavage and activation of effector caspases.42 The intrinsic route is initiated by 
cellular (DNA) damage and subsequent destabilization of the mitochondria. Release 
of membrane components of mitochondria leads to the formation of the apoptosome, 
which causes cleavage and activation of caspase 9 and subsequently effector 
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caspases.40 A less studied and less well known pathway is the endoplasmic 
reticulum (ER) pathway. Apoptosis induction via this pathway is induced by high 
levels of unfolded proteins in the ER, signaling via IRE1 can activate caspase 12, 
which leads to activation of effector caspases.39,43 
 
 
Figure 1. Overview of the general intrinsic, extrinsic and endoplasmic reticulum 
apoptosis inducing pathways. 
 
In all these pathways cleavage of caspases plays an important role, these cleavage 
cascades are tightly controlled at various levels by both inhibitors as well as 
enhancers of apoptosis. Up regulation of various inhibitors was found in several 
malignancies.44 Interestingly, in DLBCL also the expression of mediators of apoptosis 
was correlated with poor prognosis.45 Muris et al were able to identify 3 groups within 
their DLBCL patients, moreover these groups had significant differences in 
prognosis. Most striking was that the clustering was performed using only genes 
involved in apoptosis, providing extra evidence that mainly the expression of 
apoptosis regulating genes is important in prognosis in DLBCL.3 These results 
combined indicate that tight control of apoptosic processes in lymphocytes is of great 
importance in prevention of lymphoma induction. 
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4.2 BMI1 
Overexpression of BMI1 reduces sensitivity to myc induced apoptosis in murine 
primary embryonic fibroblasts46 while reduction of BMI1 expression readily induced 
apoptosis in several cancer cell lines.47 BMI1 belongs to the Polycomb-group (PcG) 
of genes that are important regulators of mammalian lymphopoiesis.48,49 Polycomb  
 
 
Figure 2. Proposed mechanism of action of BMI1 in induction of apoptosis and its 
effect on cell cycle regulation. 
 
genes were initially identified as homeobox gene regulating factors and thus involved 
in correct development of body segmentation. Members of the Polycomb group form 
protein complexes of which the composition and localization are highly regulated. 
Various complexes have been identified of which the most important appear to be 
Polycomb repressive complex (PRC)1 and PRC2. These complexes are responsible 
for gene silencing: after DNA methylation and modification of histone tails PRC2 can 
bind to the DNA and recruits PRC1 which takes care of the definitive silencing.48,50 
Apart from their function as gene silencers, members of the polycomb group can 
have other functions in cell signaling and modification of gene expression. EZH1 has 
been shown to be important in TCR signaling via interaction with ZAP70,51 while 
BMI1 is able to regulate GATA3 ubiquitination.52 
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BMI1 has been shown to be essential for self-renewal of hematopoietic and neural 
stem cells, in part through inhibition of genes regulating senescence.53 Initially BMI1 
was identified as a collaborator of myc in the development of lymphomas.54 Further 
studies demonstrated that over-expression of Bmi1 in transgenic mice results in 
down regulation of the cell cycle inhibitors p19ARF and p16INK4a, and that BMI1 
cooperates with c-myc in tumor genesis by inhibiting c-Myc-induced apoptosis 
through p14ARF.46 
P14ARF and p16INK4a are alternatively spliced products from the INK4a/ARF 
(CDKN2A) locus with no structural homology. p14ARF is involved in the induction of 
apoptosis via p53 while p16INK4a is involved in the inhibition of cell-cycle 
progression through Cyclin D1 and CDK4/6.55  Both these processes can be 
controlled by BMI1 via the INK4a/ARF locus.56 
 
 
4.3 TRAF2 
 
ABC-like DLBCL are characterized by constitutive activation of the nuclear factor B 
(NFB) pathway and poor prognosis is thought to result from this.28 An important 
adaptor molecule that is involved in NFB activation is TRAF2. TRAF2 is one of the 
TNFR-associated factor (TRAF) proteins that associate with cytoplasmic regions of 
TNFR superfamily members.  
Thus far 6 TRAF proteins, TRAF1 to TRAF6, have been identified. Activation of TNF 
superfamily members leads to recruitment of a defined set of TRAFs and other 
proteins to the receptors and transduces signals to downstream in transducing 
signals and in activation of the NFB, JNK, p38, ERK and PI3K pathways.57,58,59,60 
TRAF2 is particularly interesting because it not only activates NFB via TNFR and 
TLR superfamily pathways, it also has anti-apoptotic properties itself. TRAF2 
mediated NFB activation results in the expression of several anti-apoptotic factors, 
expression of these factors was previously found to be associated with poor clinical 
outcome in DLBCL. Moreover, TRAF2 can recruit TRAF1, cIAP1 and cIAP2 to the 
DISC complex, resulting in disruption of pro-caspase 8 cleavage into active caspase 
8.59  
22
 Figure 3. Proposed anti-apoptotic effects of TRAF2. 
 
Furthermore, TRAF2 has recently been implicated in the Endoplasmic Reticulum 
(ER) stress response resulting in apoptosis.61,62,63 ER stress can be caused by the 
accumulation of unfolded proteins in the lumen of the endoplasmic reticulum.64  
Although still controversial, it appears that TRAF2 inhibits caspase 12 cleavage and  
subsequent apoptosis by binding of TRAF2 to IRE1. Thus, TRAF2 expression may 
result in inhibition of both stress-induced apoptosis pathways and in inhibition of the 
extrinsic pathway. 
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Aim and outline of this thesis 
 
In the experiments described in this thesis we have tried to identify mechanisms 
involved in cell cycle regulation or apoptosis, which are activated in B-cell lymphomas 
and may be responsible for poor prognosis. Several techniques have been used to 
assess the expression levels of these factors in tumor cells. 
 
Chapter 2 
To determine whether expression patterns of Polycomb genes in lymphomas are 
abnormal, the situation in normal lymphoid tissue has to be determined. It was 
already known that BMI1 and EZH2 were mutually exclusively expressed with EZH2 
expression found in Ki67 positive, dividing cells, while BMI1 expression was 
restricted to Ki67 negative, resting cells. Since Polycomb proteins are capable of 
forming large complexes in order to exert its functions, it is important to determine the 
composition of these complexes in normal lymphoid tissues. 
In this chapter we tried to answer the question whether expression of the entire 
complexes, of which BMI1 and EZH2 are part of, is mutually exclusive like BMI1 and 
EZH2 expression. 
In this study we found that BMI1 and EZH2 are indeed mutually exclusively 
expressed in the vast majority of tonsillar B-cells. However, there was a small subset 
of dividing cells which expressed both BMI1 and EZH2, these cells are probably in 
transition from dividing to a resting state and do not form a stable subpopulation. Not 
all members of the BMI1 containing Polycomb responsive complex 1 (PRC1) and 
EZH2 containing PRC2 show the same expression patterns as BMI1 and EZH2, 
some complex members are expressed in all cells within the germinal center. Thus 
both complexes are expressed in all cells within the germinal center, the composition 
of each complex is dependent on cell cycle. Therefore the co expression of all 
Polycomb genes as seen in many lymphomas is an abnormal feature, whether this is 
a cause or consequence of malignant transformation needs to be determined. 
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Chapter 3 
BMI1 and EZH2 co expression was found previously in Hodgkin’s lymphoma, 
expression of the other members of the Polycomb group had previously not been 
studied. 
Here we tried to determine expression patterns of Polycomb genes in Hodgkin’s 
lymphoma and compared this with normal B-cells. 
 Hodgkin and Reed-Sternberg cells (the malignant cells in Hodgkin’s lymphoma) co-
expressed all members of both complexes. Our conclusion therefore is that both 
complexes are fully functional present in these malignant cells. We further analyzed 
p16INK4a expression in these lymphomas. In previous studies p16INK4a expression 
was found to be regulated by BMI1, in our study we found BMI1 expression in all HL 
and p16INK4a in approximately half of the HL cases. Functional repression of 
p16INK4a expression by BMI1 in HL cells is thus probably disrupted. 
 
Chapter 4 
In one of our previous studies BMI1 was found to be co-expressed with EZH2 in 
DLBCL, the expression levels of EZH2 and BMI1 were variable and elevated co-
expression was correlated with stage of disease. 
In this follow-up study we investigated whether BMI1 expression was correlated with 
prognostic clinical parameters and whether this could be explained by p14ARF and 
p16INK4a regulation. 
BMI1 and p14ARF and p16INK4a were aberrantly expressed in part of primary nodal 
DLBCL. Expression of BMI1 was related to unfavorable outcome. Down-regulation of 
tumor suppressor genes p14ARF and p16INK4a by BMI1 might explain the 
relationship between BMI1 expression and poor outcome in part of DLBCL. However, 
strong expression of p14ARF and/or p16INK4a in part of DLBCL suggests that the 
tumor-suppressive effect of these proteins is counteracted by down-stream 
mechanisms. 
 
Chapter 5 
Poor prognosis in DLBCL can be explained by inhibition of apoptosis induction, 
resulting in inefficient response to chemotherapy. TRAF2 is an important inhibitor of 
apoptosis, it is capable of inhibiting apoptosis through a variety of mechanisms, 
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TRAF2 can both induce anti-apoptotic NFB target genes as well as inhibit caspase 
cleavage directly. 
Is high TRAF2 expression in DBLCL correlated with poor prognosis? 
TRAF2 is expressed in part of ABC like DLBCL and usually not in GCB like DLBCL 
and that TRAF2 expression adds to the prognostic value of GCB versus ABC like 
profiling with regard to progression free survival time. Our data suggest that NFB 
activation may be mediated by TNF receptor superfamily or endoplasmic stress 
induced expression of TRAF2 in part of ABC like DLBCL. However, since NFB 
activation was not seen in all TRAF2 positive cases we believe that the main anti-
apoptotic mechanism through which TRAF2 causes poor prognosis is through direct 
interaction with IRE1 and subsequent prevention of caspase 12 cleavage. 
 
Chapter 6 
Clustering-analysis of DLBCL using only apoptosis genes revealed various groups 
with significant differences in prognosis. The groups as found by apoptosis-clustering 
were similar to the previously found ABC/GCB/type 3 DLBCL, which were identified 
using clustering of all genes on the micro-array.  PCLBCL, LT and PCFCL are 
phenotypically similar to ABC-DLBCL and GCB-DLBCL when the expression of all 
genes is considered. 
Can clustering using apoptosis genes only distinguish groups within PCLBCL with 
poor prognosis and can this information give us clues on the mechanism which is 
responsible for poor prognosis in PCLBCL, LT and good prognosis in PCFCL? 
Based on the expression of apoptosis regulating genes alone, PCLBCL can be 
divided into two groups, these two groups greatly overlap with the PCFCL/PCLBCL, 
LT classification. PCLBCL, LT cases are phenotypically very similar to AAC-DLBCL, 
thus, the idea that poor prognosis in AAC-DLBCL is caused by inhibition of apoptosis 
pathways involved in chemotherapy-induced cell-death may also hold true for 
PCLBCL, LT. 
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Polycomb group (PcG) genes encode two chromatin-binding protein complexes, the PRC1
and the PRC2 PcG complexes, which are essential for the maintenance of cell identity and
play a role in oncogenesis. PcG complexes were recently identified as novel regulators of
hematopoiesis, and appear to be expressed in a non-overlapping pattern in resting and
mature follicular B cells. Using highly specific antisera in combination with immunohisto-
chemistry and triple immunofluorescence, we investigated the expression pattern of nine
human PcG genes in germinal center (GC) B cells and highly purified germinal center B cell
subpopulations. PcG proteins were detected in characteristic binding patterns that were not
necessarily related to mutually exclusive expression of the two PcG complexes. We con-
clude that the two PcG complexes are expressed throughout GC development, and that the
fine composition of each complex is determined by the differentiation status of the cell. In
addition, a subset of dividing cells with a centrocyte CD marker profile was identified that co-
expresses core components of the PRC1 and PRC2 complex. We propose that these cells
reflect a transitional stage between resting and dividing follicular B lymphocytes, and that
they possibly represent the healthy precursors of nodal large B cell lymphomas.
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1 Introduction
Lymphocyte development involves complex steps of dif-
ferentiation, characterized by establishment of cell type-
specific gene expression patterns. During cell division,
the resulting gene expression and gene silencing pat-
terns must be propagated to the next generation of cells.
One group of genes that is essential for maintenance of
gene silencing belongs to the Polycomb group (PcG) [1,
2]. PcG genes were first identified in Drosophila as regu-
lators of homeobox gene expression and embryogenesis
[3]. In adults, PcG genes play a vital role in regulation of
the cell cycle and lymphopoiesis [2, 4–6].
PcG proteins function by forming DNA-binding protein
complexes that contain multiple PcG proteins and non-
PcG factors. Although the composition of these com-
plexes is variable, two fundamental and evolutionary
conserved complexes have been identified [7, 8]. In
humans, the BMI-1, MEL-18, RING, HPC and HPH PcG
proteins form the evolutionary conserved homologue of
the Polycomb repressive complex 1 (PRC1), or ‘mainte-
nance’ complex recently characterized in Drosophila [7,
9–17]. A second complex, PRC2 or ‘initiation’ complex,
is composed of the EZH, EED, YY1, and SU(Z)12 PcG
proteins, and resembles the Esc-E(Z) complex in Dro-
sophila [18–25]. These complexes are distinct, and indi-
vidual members of each complex generally do not inter-
act with each other in mature cells [8]. Except for MEL-18
[26] and YY1 [27], the majority of PcG proteins have no
direct DNA-binding capacity. PcG complexes are
thought to bind DNA through interaction with common
transcription factors [28, 29]. In addition, various other
non-PcG proteins have been identified in PcG com-
plexes, including histone methyltransferases [30, 31]
and histone deacetylases [32, 33]. The presence of
these proteins strongly suggests that alteration of
chromatin structure and modification of histone tails
contributes to the mechanism of gene silencing by PcG
complexes.
33
The role of PcG genes in lymphoid development is best
illustrated by the phenotype of mutant mice with altered
PcG genes. Conditional Enx1/EZH2 mutant mice display
decreased formation of pre-B and immature B cells in
the bone marrow, owing to reduced rearrangement of
IgH genes of the VHJ558 family and IL7-induced histone
methylation [34]. In addition, knockouts affecting the
PRC1 complex, for instance of the Bmi-1 [35], M33 [36],
Mel-18 [37], and Rae28 [38, 39] PcG genes, all resulted
in proliferative defects of lymphoid and myeloid cells and
progressive loss of B, and in some cases, T cells. Inter-
estingly, deletion of the Eed PcG gene produced
enhanced lymphoid proliferation and increased numbers
of pre-B cells [40], suggesting that a balance between
the two PcG complexes is essential for normal develop-
ment of lymphoid cells.
The role of human PcG genes in lymphoid development
receives increasing scrutiny because individual PcG
genes have been identified as oncogenes, and possibly
play a role in development of lymphoid malignancies
[41–47]. Recent studies have therefore begun to delin-
eate human PcG expression patterns during normal lym-
phopoiesis. We showed that mature B cell development
in germinal centers (GC) is associated with alternating
expression of PcG genes encoding PRC1 and PRC2 [41,
48]. Resting B cells in the mantle zone, and resting cent-
rocytes in the follicle, express BMI-1 and RING1, which
belong to the PRC1 PcG complex. Dividing follicular
centroblasts, however, do not express these genes but
employ EED and EZH2. Similar observations were made
in interfollicular T cells [49], suggesting that expression
of PRC1 and PRC2 is mutually exclusive in mature
peripheral B and T cells. This pattern does not appear to
be established at earlier stages of lymphoid develop-
ment, however, because developing B cell precursors in
the bone marrow, and developing T cells in the thymus,
go through a stage of BMI-1 and EZH2 co-expression
[49–51].
In the current study we analyzed the expression profile of
the BMI-1 and EZH2 oncoproteins in combination with
their PcG binding partners in GC cells and highly purified
GC subpopulations. Individual PcG proteins were
detected in characteristic binding patterns that were not
necessarily related to mutually exclusive expression of
the two PcG complexes. We conclude that PRC1 and
PRC2 are expressed throughout GC development and
that the fine composition of each complex is determined
by the differentiation status of the cell. Additionally, a
subset of dividing cells expressing a centrocyte CD
marker profile was identified that co-expresses all com-
ponents of PRC1 and PRC2 that we can detect with our
antibodies. We propose that these cells reflect a transi-
tional developmental stage between resting and dividing
follicular B cells, which possibly represents the healthy
counterpart of malignant nodal large B cell lymphomas
(LBCL).
2 Results
2.1 Expression of PRC1 complex PcG proteins in
germinal centers
GC are the site of B cell affinity maturation in peripheral
lymphoid tissue and contain B cells at various stages of
division and differentiation [52]. These stages correlate
with the structure of the GC, formed by a follicle sur-
rounded by a mantle zone. The GC follicle (GCF) con-
tains a dark zone (DZ) of highly proliferative centroblasts,
and a light zone (LZ) with non-proliferating centrocytes.
GCF are surrounded by naive, resting B cells, which
make up the mantle zone (MZ). Centroblasts undergo
somatic hypermutation and class switch recombination
and give rise to resting centrocytes, which are subject to
selection. To correlate PcG expression patterns with dis-
tinct steps in GC development, we detected individual
PcG proteins forming the PRC1 and PRC2 PcG com-
plexes in the three major GC B cell populations: mantle
cells, centrocytes and centroblasts.
We started our analysis by immunohistochemical detec-
tion of six PcG proteins belonging to the PRC1 PcG
complex: BMI-1, MEL-18, RING1, HPH1, HPC1, and
HPC2 (Table 1). Fig. 1 shows representative PcG stain-
ing patterns obtained from tonsil tissue, which were simi-
lar to those obtained from lymph nodes (data not
shown). Mantle cells and centrocytes in the LZ
expressed BMI-1 (Fig. 1A) and RING1 (Fig. 1B) in a
nuclear pattern and at variable intensity; centroblasts in
the DZ were negative for these proteins. By contrast,
examination of the staining profile of BMI-1 and RING1
binding partners, HPH1, HPC1, HPC2, and MEL-18
revealed strongly divergent patterns. HPH1 followed the
BMI-1 and RING1 staining profile and was detectable in
the MZ and LZ centrocytes (Fig. 1C). Whereas HPC1
(Fig. 1D) was undetectable in GC, HPC2 (Fig. 1E) was
expressed constitutively in the MZ and throughout the
GCF. Finally, MEL-18 (Fig. 1F) was weakly expressed in
large blastoid cells resembling centroblasts and gener-
ally undetectable in centrocytes and mantle cells.
2.2 Expression of PRC2 complex PcG proteins in
GC
Analysis of the PRC2 complex was performed by detec-
tion of the EED, EZH2, and YY1 PcG proteins (Table 1).
EED and EZH2 were detected primarily in large
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Table 1. Antibodies and staining conditions for immunohistochemistry and immunofluorescencea)
Antibody against Type of antibody Pre-incubation IHC detection IF detection
BMI-1 Rabbit polyclonal NSS ABC/CARD –
BMI-1 Mouse monoclonal NRS – Rhodamine/tyramine
FITC/tyramine
RING1 Rabbit polyclonal NSS ABC/CARD G § R-ALEXA488
HPH-1 Rabbit polyclonal NSS ABC/CARD G § R-ALEXA488
HPC-1 Rabbit polyclonal NSS ABC/CARD G § R-ALEXA488
HPC-2 Rabbit polyclonal NSS ABC/CARD G § R-ALEXA488
MEL-18 Goat polyclonal NSS ABC/CARD –
EED Mouse monoclonal NRS ABC/CARD Streptavidin-APC
EZH2 Rabbit polyclonal NSS ABC/CARD G § R-ALEXA488
YY1 Mouse monoclonal UV-Block Ultra Vision Streptavidin-APC
Ki-67 (MIB-1) Mouse monoclonal UV-Block Ultra Vision Streptavidin-APC
G § M-TRITC
a) NSS: normal swine serum (DAKO); NRS: normal rabbit serum (DAKO); UV Block: UltraVision Block solution (Lab Vision); ABC/
CARD: horseradish-peroxidase-conjugated streptavidin-biotin-complex/catalyzed reporter deposition method (DAKO). YY1
and MEL-18 were obtained from Santa Cruz (CA), MIB-1 was purchased from DAKO.
Table 2. PcG gene expression in purified follicular B cell subpopulations
PRC1 complex PRC2 complex Ki-67
BMI-1 RING1 HPH-1 HPC-1 HPC-2 EED EZH2 YY1
IgD+/CD38Low+
mantle cells
+ + + – + – – + –
CD10+/CD77+
centroblasts
– – – – + + + + +
CD10+/CD77–
centrocytes
– – – – + + + + +
+ + + – + + + + +
+ + + – + – – + –
centroblast-like follicular B cells, whereas mantle cells
and LZ centrocytes did not stain for these proteins
(Fig. 1G, H). By contrast, the EED binding partner YY1
(Fig. 1I) was expressed constitutively throughout the
GCF and in the MZ (Table 2).
2.3 Detection of PcG proteins by triple
immunofluorescence and confocal laser
scan microscopy
PcG proteins were detected in combination with Ki-67, a
marker for cycling cells, to correlate PcG expression pro-
file with proliferation status. In agreement with earlier
findings [41, 48, 49], EZH2 was expressed in the
absence of BMI-1 in Ki-67+ dividing follicular cells, con-
firming the staining profile of centroblasts (not shown).
Triple immunofluorescence analysis of BMI-1 in combi-
nation with EZH2 and EED (Fig. 2A) showed that BMI-1
expression reflected the centrocyte staining pattern and
was associated with EED–/EZH2– resting cells. EED was
only detectable in EZH2+ cells, which are Ki-67+ and
cycling [48, 49]. These observations are in line with the
fact that EED and EZH2 are binding partners [19, 21, 22],
and show that expression of EZH2 and EED in GC is
separated from BMI-1. By contrast, the EED binding
partner YY1 was detected throughout the GCF in both
resting (BMI-1+/EZH2–) and cycling (BMI-1–/EZH2+) cells
(not shown).
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Fig. 1. Immunohistochemical detection of human PcG proteins in tonsillar GC. (A–F) Detection of PcG proteins belonging to the
PRC1 PcG complex (A: BMI-1; B: RING1; C: HPH1; D: HPC1; E: HPC2; F: MEL-18). (G–I) detection of PcG proteins belonging to
the PRC2 PcG complex (G: EED; H: EZH2; I: YY1). Insets show details of large blastoid centroblasts and small centrocytes. MZ:
mantle zone; DZ: dark zone; LZ: light zone.
Immunofluorescence detection of the PRC1 proteins
RING1, HPH-1 and HPC1/2 further confirmed the results
obtained by immunohistochemistry. RING1 and HPH1
displayed an expression profile that was identical to the
pattern of BMI-1: these proteins were present in the
nuclei of BMI-1+/Ki-67– resting cells and were unde-
tected in the nuclei of EZH2+/Ki-67+ cells (not shown).
Analysis of HPC-2 in combination with BMI-1 and EED
(Fig. 2B) showed that HPC2 was detectable throughout
the GC, and present in both BMI-1+/EED– (resting) cells
and BMI-1–/EED+ (cycling) cells. By contrast, we were
unable to detect HPC1 in the GC (Fig. 2C).
2.4 PcG expression in FACS-purified GC
subpopulations
Because immunohistochemical and immunofluores-
cence analysis of PcG expression in mantle cells, centro-
cytes and centroblasts was based on the presence of Ki-
67 and morphological characteristics of follicular B cells,
we verified the PcG expression patterns in highly
enriched GC B cell subpopulations. To this end, cell sus-
pensions were prepared from fresh tonsils and CD3+ T
cells were removed by magnetic beads. B cells were
then FACS purified into a CD10+CD77+ and a
CD10+CD77– fraction (centroblasts and centrocytes,
respectively) and IgDLow+CD38+ mantle cells [53, 54].
Fig. 3 represents a typical experiment and shows that
GC subpopulations were enriched to G 90% purity (91%
mantle cells, 95% centroblasts, and 90% centrocytes).
Given the close association between PcG expression
profiles and proliferation status, purified GC subpopula-
tions were tested for expression of the Ki-67 antigen to
determine their proliferative activity. The vast majority
( G 99%) of IgDLow+CD38+ mantle cells were resting and
Ki-67–, while virtually all ( G 99%) CD10+CD77+ centrob-
lasts expressed Ki-67 and were in cycle (Fig. 3). By con-
trast, the CD10+CD77– centrocyte-enriched fraction rep-
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Fig. 2. Detection of human PcG proteins in GC using triple immunofluorescence. Immunofluorescence detection of BMI-1, EED,
EZH2, HPC-2 and HPC-1 Pc-G proteins in secondary GC of human tonsil. BMI-1 is detected using red fluorescence, EED is
detected with blue fluorescence and EZH2, HPC-1 and HPC-2 are detected with green fluorescence. In the left four panels (A)
BMI-1/EED/EZH2 triple stainings are shown, in the center four panels (B) BMI-1/EED/HPC2 triple stainings are shown, and in the
right four panels (C) BMI-1/EED/HPC1 triple stainings are shown.
resented a mixed population and contained an estimated
40% of Ki-67+ dividing cells (Fig. 3). To exclude the pos-
sibility that this subpopulation was activated during the
isolation procedure, we fixed the cell suspensions using
1% paraformaldehyde prior to removal of CD3+ T cells
and FACS purification. Subsequent analysis of Ki-67
expression revealed a similar distribution of Ki-67+ cells
compared to unfixed cells (data not shown). From these
data we concluded that the presence of Ki-67+ cells
within the CD10+CD77– subpopulation was not caused
by activation during the isolation procedure, and that
CD10+CD77– follicular B cells represent a mixed popula-
tion of cycling and non-cycling cells.
Immunofluorescence detection of BMI-1, EZH2, and Ki-
67 in purified mantle cells and centroblasts, revealed that
these GC subpopulations stained for BMI-1 and EZH2 in
a pattern that was identical to the pattern observed in
whole tissue sections. Ki-67–IgDLow+CD38+ mantle cells
expressed BMI-1 in the absence of EZH2, whereas Ki-
67+CD10+CD77+ centroblasts expressed EZH2 in the
absence of BMI-1 (Table 2). By contrast, analysis of the
CD10+CD77– fraction enriched for centrocytes, revealed
three distinct major subpopulations based on expression
of Ki-67, BMI-1, and EZH2 (Fig. 4). In agreement with
immunohistochemical analysis (Fig. 1), the majority of
CD10+CD77– cells was Ki-67–, while an estimated 40%
of the CD10+CD77– cells expressed Ki-67 (Fig. 4A).
Staining for EZH2 in combination with Ki-67 revealed
that Ki-67 expression within the CD10+CD77– population
fully overlapped with expression of EZH2 (Table 2 and
not shown). In contrast to the staining profile of Ki-
67+CD10+CD77+ centroblasts, most CD10+CD77– cent-
rocytes expressing Ki-67 were found to be BMI-1+
(Fig. 4A). Together, these findings suggested that
CD10+CD77– cells must contain a sub-population of lym-
phocytes that co-express BMI-1 and EZH2. A BMI-1+/
EZH2+ population of cells was indeed detected after
staining of CD10+CD77– lymphocytes for BMI-1 and
EZH2 (Fig. 4B), and is also visible in tissue sections of
tonsils (indicated by arrows and inset in Fig. 2A). We
conclude that the CD10+CD77– centrocyte-enriched GC
fraction consists of three subpopulations that are either
BMI-1+/EZH2+/Ki-67+ (34%, 5% of total tonsillar B cells),
BMI-1–/EZH2+/Ki-67+ (10%, 1.5% of total tonsillar B
cells) or BMI-1+/EZH2–/Ki-67– (56%, 8% of total tonsillar
B cells).
Finally, analysis of BMI-1 and EZH2 binding partners in
IgDLow+CD38+, CD10+CD77+, and CD10+CD77– GC sub-
populations corroborated the patterns established ear-
lier on whole tissue (Table 2). Expression of EED fully
overlapped with expression of EZH2 (not shown), and
expression of BMI-1 coincided with detection of RING1
(Fig. 4C) and HPH1 (not shown). Whereas HPC2 (Fig. 4D)
and YY1 (not shown) were detected in all three subpopu-
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Fig. 3. Purification of GC B cell subpopulations. Follicular B cells were separated from T lymphocytes by CD3-coated magnetic
beads, and incubated with combinations of anti-CD10-PE, anti-CD77-FITC, anti-CD38-APC and anti-IgD-PE. Cells were then
FACS separated into a IgDLow+/CD38+, CD10+/CD77–, and CD10+/CD77+ populations, enriched for mantle cells, centrocytes, and
centroblasts, respectively. Pictures of cytospin preparations shown on the right, reveal Ki-67 expression in the separated frac-
tions.
lations, none of these expressed HPC1. We were unable
to determine the expression pattern of MEL-18 in combi-
nation with other PcG proteins, because the MEL-18
antiserum could not be used for immunofluorescence
due to our inability to generate a specific signal using this
antiserum.
3 Discussion
An essential aspect of lymphopoiesis is maintenance of
cell identity after a particular pathway of lineage-specific
development is chosen. PcG genes encode a ‘cellular
memory’ system that plays an essential role in this pro-
cess. The hallmark of PcG function is the maintenance of
gene silencing patterns during cell division, which con-
tributes to retention of characteristic gene expression
patterns by daughter cells. PcG genes are expressed
throughout mammalian lymphoid development, and their
essential role in this process is underscored by the
occurrence of severe hematopoietic defects in PcG
mutant mice. These defects can occur early in lymphoid
development, as shown for instance by arrested devel-
opment of double-negative thymocytes in M33, MEL-18
and Rae28 knockout mice, and a lack of response to IL-
7-mediated stimulation of pro-B cells in Bmi-1-deficient
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Fig. 4. Detection of human PcG proteins in purified CD10+/CD77– centrocytes using double immunofluorescence. Immunofluo-
rescence detection of BMI-1, EZH2, RING1, HPC2 and Ki-67 in separated CD10+/CD77– centrocytes. Left four panels: staining
for BMI-1 (red) in combination with Ki-67 (green), revealing BMI-1+/Ki-67+ cells (dashed arrow), BMI-1+/Ki-67– cells (arrow) and
BMI-1–/Ki-67+ cells (*). Middle four panels: staining for BMI-1 (red) in combination with EZH2 (green), revealing BMI-1+/EZH2+
cells (arrow), BMI-1+/EZH2– cells (dashed arrow). EZH2 is a nuclear protein, and we only consider cells with abundant nuclear
staining for EZH2 positive. In some instances, atypical dotted or ring-like EZH2 staining is visible at the edges of cells, which
most likely reflects faint (cytoplasmic) background staining. The two panels on the right show stainings for BMI-1 (red) in combi-
nation with RING1 (green, top) and HPC2 (green, bottom). Expression of BMI-1 overlaps with RING1 and HPC2.
Fig. 5. Hypothetical model of PcG gene expression and PcG complex composition during GC development. The transition of
resting Ki-67– mantle cells to dividing Ki-67+ centroblasts is associated with loss of BMI-1, RING1, and HPH1, and appearance
of MEL-18, EZH2, and EED, during antigen activation. The subsequent development of dividing Ki-67+ centroblasts into resting
Ki-67– centrocytes is associated with re-appearance of BMI-1, RING1, and HPH-1, and loss of MEL-18, EZH2 and EED. The
hypothetical intermediate stage between centroblasts and centrocytes has a centrocyte-like CD marker profile but morphologi-
cally resembles centroblasts, and expresses all investigated core components of the PRC1 and PRC2 PcG complexes.
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mice [35–39]. However, the deficiency in Th2 develop-
ment in mice with a disrupted Mel-18 gene [55] shows
that PcG genes can also affect more mature stages of
lymphoid development.
We recently demonstrated that follicular B cells in GC
express components of the two human PcG complexes
in a mutually exclusive pattern [41, 48]. The BMI-1 and
RING1 PcG genes were detected in resting Ki-67– mantle
cells and resting Ki-67– centrocytes, whereas dividing Ki-
67+ centroblasts were associated with expression of the
EZH2 and EED PcG genes. From these observations we
concluded that expression of the two human PcG com-
plexes is mutually exclusive and depends on the activa-
tion and differentiation status of follicular B cells. Recent
studies of in vitro activated B cell subpopulations sup-
port this conclusion. For instance, microarray analysis of
activated plasma cells revealed non-overlapping expres-
sion patterns of BMI-1 and EZH2 in resting plasma cells
and proliferating plasmablasts, respectively [56]. Simi-
larly, BCR ligation of normal resting splenic B lympho-
cytes results in up-regulation of EZH2 in activated cells
expressing Ki-67/MIB-1[57]. The expression patterns of
BMI-1 and EZH2 binding partners determined in the cur-
rent study, however, show that the situation is more com-
plex and that individual components of the two com-
plexes display distinct expression profiles. Thus, the
PRC1 complex is represented by BMI-1, RING1, HPH1,
and HPC2 in resting follicular B cells, and by MEL-18 and
HPC2 in dividing follicular B cells. Conversely, the PRC2
PcG complex is represented by YY1 in resting cells, and
by YY1, EED, and EZH2 in dividing cells. Our interpreta-
tion of these patterns is that antigen-dependent devel-
opment of follicular B cells is associated with strict regu-
lation of PcG expression, and that components of both
PcG complexes co-exist throughout GC development.
The PcG expression patterns suggest that the fine com-
position of PcG complexes depends on the proliferation
and differentiation status of the follicular B cell (Fig. 5).
The transition of resting Ki-67– mantle cells to dividing Ki-
67+ centroblasts is associated with loss of BMI-1,
RING1, and HPH1, and appearance of MEL-18, EZH2,
and EED, during antigen activation. The subsequent
development of dividing Ki-67+ centroblasts into resting
Ki-67– centrocytes is associated with re-appearance of
BMI-1, RING1, and HPH-1, and loss of MEL-18, EZH2
and EED. These patterns are in line with the rapid
changes in expression of individual PcG genes observed
after B cell antigen receptor cross-linking [58], and the
induction of EZH2 expression in cycling B cells [57, 59].
An important question that needs to be addressed in
future studies is what is the functional consequence of
the distinct PcG expression patterns during lymphoid
development. In this regard, our observation that PcG
homologues like BMI-1/MEL-18, and HPC1/HPC2 have
opposing expression patterns during GC development,
may be relevant. These results are in agreement with
previous studies, which showed that PcG homologs are
expressed in distinct and often contrasting patterns. For
instance, RT-PCR analysis of the Enx2/EZH1 and Enx1/
EZH2 PcG genes during mouse B cell differentiation
showed that Enx1/EZH2 expression decreases during
development of pro-B cells into immature/recirculating B
cells, whereas Enx2/EZH1 was expressed in an oppos-
ing pattern [34]. In some instances these disparities may
reflect differences in function or biochemical behavior.
BMI-1, for example, has no DNA-binding activity and is
classified as an oncogene [60, 61], whereas MEL-18
binds to DNA and acts as a tumor suppressor [26, 62].
HPC2 binds the CtBP protein through the PI/LDL motif,
whereas HPC1 does not because it lacks this domain
[63]. The functional differences between closely related
PcG homologues may contribute to diversity in PcG
complex composition, which could result in different tar-
get gene affinity [8]. Therefore, alternating expression of
individual PcG proteins during GC development may be
related to formation of distinct PcG complexes in differ-
ent follicular B cell sub-populations, and induction of dif-
ferent gene silencing patterns in these cells.
An alternative, and not necessarily mutually exclusive,
explanation for the discrete PcG expression patterns in
cycling and resting follicular B cells is that they reflect
different stages in gene suppression. In this regard, two
observations are relevant. First, the vast majority of
mature follicular B cells do not co-express core compo-
nents (BMI-1/RING1/HPH1 and EED/EZH2) of the two
human PcG complexes in the same nucleus ([41, 48],
and this study), and expression of these genes is sepa-
rated according to proliferation status. However, double
expression of BMI-1 and EZH2 is frequent in developing
lymphoid precursors, such as differentiating B cells in
the bone marrow [50, 51], and double-negative thymo-
cytes [49]. Second, current models of gene silencing by
PcG proteins in Drosophila predict that core proteins of
the PRC1 and PRC2 PcG complexes are transiently pre-
sent at the same time, while some individual compo-
nents of these complexes interact, while gene silencing
is established [64]. This process is thought to occur in
discrete steps, involving deacetylation of histone H3 res-
idues by HDAC in the PRC2 complex, followed by meth-
ylation of histone H3 by the histone methyltransferase
SUV39H1 and recruitment of the PRC1 complex [31].
These findings collectively suggests that the distinct
expression patterns of PRC1 and PRC2 complex core
components in resting and cycling follicular B cells
reflect discrete stages in PcG-mediated gene silencing.
Although it is formally possible that diverse PcG expres-
sion patterns in centrocytes reflect separate subpopula-
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tions, we hypothesize that Ki-67+CD10+CD77– follicular B
cells co-expressing PRC1 and PRC2 core components
represent a transitional stage in the establishment of
gene silencing in follicular B cells (Fig. 5). An interesting
aspect of the PcG expression pattern in centrocytes is
that co-expression of the major components of the
PRC1 and PRC2 complex has also been observed in Ki-
67+ neoplastic cells of nodal LBCL and Reed-Sternberg
cells of Hodgkin’s lymphoma [41–43, 59, 65]. Given the
fact that follicular B cells are the normal counterparts of
neoplastic cells in nodal LBCL, we speculate that Ki-
67+CD10+CD77– centrocytes, co-expressing the main
PcG proteins of the two PcG complexes, are the healthy
precursors of neoplastic cells in nodal LBCL.
4 Materials and methods
4.1 Tissue collection
Hyperplastic, non-malignant tonsils and lymph nodes were
collected from healthy individuals at the Department of
Pathology of the VUMC (Vrije Universiteit Medical Center).
Tissues were either fixed in 4% buffered formalin for immu-
nohistochemistry, immediately frozen in liquid nitrogen for
confocal laser scan microscopy, or mechanically dissoci-
ated and frozen for FACS experiments.
4.2 Purification of centrocytes, centroblasts and
mantle cells from tonsils
Centrocytes, centroblasts and mantle cells were purified
according to established protocols on the basis of CD10,
CD38, CD77 and IgD expression profiles [53, 54]. Briefly,
fresh tonsils were mechanically dissociated and T lympho-
cytes were depleted with CD3-coated Dynabeads (Dynal,
Oslo, Norway). The CD3– fraction was used for FACS sorting
of IgDLow+CD38+ mantle cells, CD10+CD77+ centroblasts and
CD10+CD77– centrocytes. Cells were incubated with
phycoerythrin-labeled antibody against CD10 (Becton Dick-
inson, San Jose, CA), fluorescein-labeled antibody against
CD77 (PharMingen, San Diego, CA), allophycocyanin-
labeled antibody against CD38 (Becton Dickinson) and
phycoerythrin-labeled antibody against IgD (PharMingen).
After staining with the appropriate antibody, cells were FACS
sorted using a MoFlo (Cytomation, Fort Collins, CO) to a
purity of G 90% (Fig. 1).
4.3 Immunohistochemical detection of PcG proteins in
cytospins of sorted cell populations
Sorted cells were fixed in 1% formaldehyde (Merck, Darms-
tadt, Germany) in PBS for 10 min and used for cytospin
preparations (kept frozen at –20°C until used). For immuno-
histochemical detection of PcG proteins, slides were thawed
and dried for 1 h at room temperature. They were fixed for
15 min with 3% formaldehyde in PBS. Endogenous peroxi-
dase was inhibited by a 30-min incubation with 1% H2O2
(Merck) in PBS. Antigens were retrieved in citrate buffer (pH
6.0) by boiling for 10 min in a microwave, followed by 5-min
incubation in 0.5% Triton X-100 (BDH, Poole, GB) in PBS
and 10-min incubation in 0.1 M glycine (Merck) in PBS.
Slides were pre-incubated for 10 min with Ultra Vision Block
solution (Lab Vision, Fremont, CA). Primary antibodies were
applied overnight at 4°C. The secondary antibody, Ultra
Vision large volume biotinylated goat anti-mouse, was
added and after rinsing in PBS, Ultra Vision large volume
streptavidin peroxidase was applied. Staining was per-
formed using 3-amino-9-ethylcarbazole (AEC) (Zymed, San
Francisco, CA) and sections were counterstained with
hematoxylin. All steps were performed in the presence of
0.1% saponin (Sigma, Steinheim, Germany).
4.4 Immunohistochemistry on tissue sections
Immunohistochemical staining was performed as described
previously [42]. Briefly, endogenous peroxidase was inhib-
ited with 0.3% H2O2 in methanol. Following antigen retrieval,
primary antibodies and secondary antibodies were applied
(Table 1), and immunostaining was performed with AEC
using either horseradish peroxidase-conjugated
streptavidin-biotin-complex (sABC-HRP) and further signal
enhancement by the catalyzed reporter deposition (CARD)
method (DAKO), or using the Ultra Vision method (Lab
Vision) following the protocol supplied by the manufacturer.
4.5 Confocal laser scan microscopy on frozen tonsil
sections and cytospins of tonsil populations
Confocal laser scan microscopy was performed on frozen
tissue as described previously [43, 49, 65]. Briefly, sections
were fixed 1% formaldehyde/PBS, and endogenous peroxi-
dase was inhibited by incubation in 1% H2O2/PBS. Appro-
priate primary and secondary antibodies were added, and
detected with labeled antibodies as indicated in Table 1.
Slides were covered using ProLong (Molecular Probes) and
analyzed using a Leica DMR confocal laser scan micro-
scope. Images were stored at 1024 dpi and processed using
Adobe PhotoShop 6.
Double stainings of cytospins were performed as described
above with a few adaptations. After incubation with H2O2,
the slides were boiled in the microwave in citrate buffer
(pH 6.0) and incubated for 5 min in 0.5% Triton X-100 and
for 10 min in 0.1 M glycine. Staining was performed like
above but BMI-1 was detected using either rhodamine or
fluorescein isothiocyanate-conjugated tyramine and Ki-67
was detected using G § M IgG1TRITC (Southern Biotechnology
Associates).
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Human Polycomb-group (PcG) genes play a crucial
role in the regulation of embryonic development and
regulation of the cell cycle and hematopoiesis. PcG
genes encode proteins that form two distinct PcG
complexes, involved in maintenance of cell identity
and gene silencing patterns. We recently showed that
expression of the BMI-1 and EZH2 PcG genes is sep-
arated during normal B-cell development in germinal
centers, whereas Hodgkin/Reed-Sternberg (H/RS)
cells co-express BMI-1 and EZH2. In the current
study, we used immunohistochemistry and immuno-
fluorescence to determine whether the binding part-
ners of these PcG proteins are also present in H/RS cells
and H/RS-derived cell lines. PcG expression profiles
were analyzed in combination with expression of the
cell cycle inhibitor p16INK4a, because experimental
model systems indicate that p16 is a downstream target
of Bmi-1. We found that H/RS cells and HL-derived cell
lines co-express all core proteins of the two known PcG
complexes, including BMI-1, MEL-18, RING1, HPH1,
HPC1, and -2, EED, EZH2, YY1, and the HPC2 binding
partner, CtBP. Expression of HPC1 has not been found
in normal mature B cells and other malignant lympho-
mas of B-cell origin, suggesting that the PcG expression
profile of H/RS is unique. In contrast to Bmi-1 trans-
genic mice where p16INK4a is down-regulated, 27 of 52
BMI-1POS cases of HL revealed strong nuclear expres-
sion of p16INK4a. We propose that abnormal expression
of BMI-1 and its binding partners in H/RS cells contrib-
utes to development of HL. However, abnormal expres-
sion of BMI-1 in HL is not necessarily associated with
down-regulation of p16INK4a. (Am J Pathol 2004,
164:873–881)
Hodgkin Lymphoma (HL) is a malignant proliferation of
mature lymphocytes, characterized by the presence of
low numbers of neoplastic cells surrounded by high num-
bers of reactive T and B lymphocytes, histiocytes, and
eosinophils.1 The neoplastic cells in HL are the Reed-
Sternberg cells (RS cells) and their mononuclear variants,
the Hodgkin cells (H cells). The majority of classical H/RS
cells are thought to be clonal expansions originating from
germinal center B cells.2–4 The exact mechanism respon-
sible for malignant transformation and subsequent devel-
opment of HD is unclear. Various mechanisms might be
involved, including aberrant expression of tumor necrosis
factor family members,5 infection with Epstein-Barr vi-
rus,6 and deregulation of the apoptosis pathway.7,8 We
recently proposed that altered expression of Polycomb-
group (PcG) genes could also contribute to malignant
transformation.9
PcG genes play a crucial role in embryonic develop-
ment and have been associated with regulation of hema-
topoiesis and the cell cycle.10–17 PcG proteins form two
evolutionary conserved multimeric complexes, that bind
to DNA and maintain cell identity by gene suppres-
sion.18,19 The PRC1/HPC-HPH “maintenance” complex is
the mammalian counterpart of the Drosophila Polycomb
repressive complex 1 (PRC1) and contains the BMI-1,
RING1, HPH, and HPC PcG proteins, and probably MEL-
18.20–27 The PRC2/EED-EZH or Esc-Ez “initiation” com-
plex, is much smaller and is composed of the EED, EZH,
SU(Z)12, and YY1 PcG proteins.28–33 PcG complexes
can contain various transcription factors that may con-
tribute to DNA binding.34,35 In addition, the presence of
histone-methyltransferases and histone deacetylases
strongly suggests that PcG complexes silence genes by
histone modification.36–39
The essential role of PcG genes in maintenance of
cellular identity and normal cellular development is re-
flected by the relationship between abnormal PcG gene
expression and malignant transformation. The best-
known example is the Bmi-1 transgenic mouse, where
Bmi-1 up-regulation induces down-regulation of p16INK4a
and p19ARF, increased lymphoid proliferation, and devel-
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opment of lymphomas.40–42 Various BMI-1 binding part-
ners have also been associated with malignant transfor-
mation, but appear to do so by mechanisms that do not
involve the p16 pathway.22,43 In addition, overexpression
of the Eed PcG gene results in diminished lymphoprolif-
eration, suggesting that the two PcG complexes have
opposing effects.44 We recently discovered that predom-
inance of PcG proteins associated with the PRC1/HPC-
HPH complex is associated with resting cells in the ger-
minal center, whereas predominance of PRC2/EED-EZH
PcG complex proteins is related to proliferation.45,46 The
opposing effects on lymphoproliferation in Bmi-1- and
Eed-transgenic mice, and the PcG expression profiles in
human germinal centers, suggest that a balance be-
tween the two PcG complexes is essential for proper
regulation of lymphoproliferation.
Despite the correlation between malignant transforma-
tion and altered expression of PcG genes observed in
experimental models, the role of human PcG genes in
oncogenesis remains relatively unexplored. Previous
data of our group showed that H/RS cells and neoplastic
cells in high-grade large B-cell lymphomas and mantle-
cell lymphomas are associated with nuclear co-expres-
sion of BMI-1 and EZH2.9,47,48 Co-expression of these
two PcG genes is generally not observed in the normal
counterparts of these cells,45,46 suggesting that aberrant
PcG expression contributes to development of malignant
lymphomas in man. It is unclear, however, whether BMI-1
expression in EZH2POS malignant lymphomas has func-
tional consequences for development of these tumors.
One condition that should be met is that binding partners
of BMI-1 and EZH2 are present in the tumor cells. In the
current study, we investigated whether H/RS cells and
HL-derived cell lines express other components of the
PRC1/HPC-HPH- and PRC2/EED-EZH PcG complexes,
and compared these patterns with the PcG expression
profile of normal B cells. In addition, PcG expression was
correlated with p16INK4a expression.
Materials and Methods
Cell Lines
The characteristics of the HL-derived cell lines L428 and
L1236 were described in detail previously.49 Cell lines
were maintained in RPMI 1640 (BioWhittaker, East Ruth-
erford, NJ) medium supplemented with 25 mmol/L
HEPES, 2 mmol/L L-glutamine, 10% fetal calf serum, 100
IU of streptomycin, and 100 g of penicillin at 37°C in 5%
CO2.
Human Tissue
Formalin-fixed, paraffin-embedded tissue blocks of 54
primary biopsies of nodular sclerosing HL patients were
retrieved from the Department of Pathology, LUMC, The
Netherlands. Frozen tissue was retrieved from 24 cases
as well. All cases were diagnosed between 1990 and
2001 and classified according to the World Health Orga-
nization new classification. The diagnostic immunohisto-
chemical panel always included CD3, CD15, CD20,
CD30, CD45, EMA, ALK1, LMP1, and EBER RNA in situ
hybridization. This panel was extended if necessary for
appropriate diagnosis. Only the first diagnostic biopsy
specimen of the patients was investigated. As positive
controls for immunohistochemistry, both paraffin-embed-
ded and frozen material from tonsil, thymus, kidney, and
testis was used (Table 1).
Immunohistochemistry
For immunohistochemistry, 3-m sections of paraffin-em-
bedded material were used for the detection of various
PcG proteins and cell cycle-related proteins Ki67 and
p16 (Table 1). After rehydration, endogenous peroxidase
was quenched by incubation of the sections in 0.3%
H2O2 diluted in methanol for 30 minutes. Thereafter, an-
tigen retrieval was performed using either citrate (pH 6.0)
Table 1. Antibodies Used in this Study in Combination with Staining Conditions
Antigen Antibody Species Subtype Titer Fluorochrome Treatment Control tissue
EED M26 Mouse IgG1 1:4000 o/n strepAPC Citrate ABC/CARD Tonsil
EZH2 K358 Rabbit 1:400 o/n GaRALEXA 488 EDTA ABC/CARD Tonsil
HPC1 K350 Rabbit 1:100 o/n GaRALEXA 488 EDTA ABC/CARD Kidney
HPC2 K326 Rabbit 1:100 o/n GaRALEXA 488 EDTA ABC/CARD Tonsil
HPH1 K344 Rabbit 1:100 o/n GaRALEXA 488 EDTA ABC/CARD Tonsil
RING1 K320 Rabbit 1:100 o/n GaRALEXA 488 Citrate ABC/CARD Tonsil
BMI-1 K333 Rabbit 1:2000 o/n GaRALEXA 488 Citrate ABC/CARD Tonsil
BMI-1 6C9 Mouse IgG2b undiluted Rhodamine/tyramine Citrate ABC/CARD Tonsil
Ki67 Mib-1 Mouse IgG1 strepAPC Citrate ABC/CARD Tonsil
MEL-18 Rabbit 1:400 o/n GaRALEXA 488 Citrate ABC/CARD Tonsil
YY1 Mouse IgG1 1:250 o/n strepAPC Citrate ABC/CARD Testis
CtBP Rabbit 1:4000 o/n GaRALEXA 488 Citrate ABC/CARD Testis
P16 Mouse IgG2a 1:500 Rhodamine/tyramine Citrate ABC/CARD Cervix carcinoma
Abbreviations: o/n, overnight at 4°C; citrate, antigen retrieval using 0.01M citrate; pH 6.0, 15 minute in the autoclave; EDTA, antigen retrieval using
10mM EDTA, pH 8.0, 15 minute in the autoclave; strepAPC, allophycocyanin-conjugated streptavidine (blue signal); GaRALEXA, ALEXA 488-conjugated
goat-anti-rabbit (green signal); rhodamine/tyramine (red signal); ABC, horseradish-peroxidase-conjugated streptavidin-biotin-complex; CARD,
catalyzed reporter deposition method. For details about isolation and characterization of PcG-specific antisera: see references in Materials and
Methods section.
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or EDTA (pH 8.0), depending on the antigen (Table 1), for
15 minutes in the autoclave. After cooling, the slides were
rinsed with phosphate-buffered saline (PBS) containing
0.5% Triton X-100 (5 minutes), followed by PBS only (3 
5 minutes). Subsequently, the slides were incubated with
0.1 mol/L glycine (10 minutes) and rinsed in PBS.
After pre-incubation with normal swine serum or nor-
mal rabbit serum, for polyclonal and monoclonal antibod-
ies, respectively, the primary antibodies26,27,31,43,50,51
were applied at optimal dilution (Table 1). Secondary
antibodies were biotinylated swine anti-rabbit or biotinyl-
ated rabbit-anti-mouse (Dako, Glostrup, Denmark). This
was followed by application of horseradish peroxidase-
conjugated streptavidine-biotin-complex (sABC-HRP)
and further signal enhancement was achieved by the
CARD-method (catalyzed reporter deposition method,
DAKO). The signal was visualized by 3-amino-9-ethylcar-
bazole (AEC) and counterstained with hematoxylin. Pho-
tographs were taken with a Zeiss Axiophot microscope
(Zeiss, Oberkochen, Germany) and were digitized using
an Agfa duoscan (Agfa, Morstel, Belgium).
Double and Triple Immunofluorescence
To confirm PcG protein staining patterns in neoplastic
cells and the surrounding infiltrate, immunofluorescent
double and triple staining was performed. This also al-
lowed us to study PcG proteins in relation to other mark-
ers, such as p16INK4a, CtBP, and Ki67. Frozen tissue
sections were fixed in 1% formaldehyde, followed by
quenching of endogenous peroxidase using 1% H2O2
diluted in PBS. After preincubation with 5% bovine serum
albumin (BSA), a combination of two or three primary
antibodies was applied overnight at 4°C. BMI-1 was de-
tected by incubation with HRP-conjugated goat-anti-
mouse IgG2b and subsequent rhodamine/tyramine inten-
sification. Detection of HPC1, HPC2, HPH1, RING1,
EZH2, YY1, p16, and CtBP was performed by incubating
the slides with ALEXA 488-conjugated goat-anti-rabbit
antiserum. The other markers were visualized by incubat-
ing the slides with biotinylated goat-anti-mouse IgG1 or
IgG2a, depending on Ig-subclass of the primary anti-
body, followed by allophycocyanin-coupled streptavidin.
Cross-reactivity of the antisera was excluded by appro-
priate controls and for each double- or triple-immunoflu-
orescence experiment; single-staining controls were in-
cluded. In addition, positive and negative controls were
routinely included. Sections were analyzed with a Leica
DMR confocal laserscan microscope (Leica, Deerfield,
IL). Images were stored digitally and processed using
Adobe Photoshop 6.
Evaluation of Immunohistochemical Staining
Percentages of PcG expressing H/RS cells were deter-
mined visually and classified according to the percent-
age of positively staining tumor cells: 0, no staining in
H/RS cells; 1, 25% of the H/RS cells positive; 2, 25%
and 50% H/RS cells positive; 3, 50% and 75% H/RS
cells positive; 4, 75% of the H/RS cells showed positive
staining. In all cases, except for HPC1, small reactive
lymphocytes served as an internal positive control.
Results
PcG Expression in Neoplastic H/RS Cells in
Hodgkin’s Lymphoma
We analyzed the expression of various components of
the PcG PRC1/HPC-HPH complex (BMI-1, HPC1, HPC2,
HPH1, RING1, MEL-18, and CtBP) and the PRC2/EED-
EZH PcG complex (EED, EZH2, and YY1) by immunohis-
tochemistry in 54 cases of HL (all cases classified as
nodular sclerosing). For all stainings, appropriate con-
trols were included (Table 1).
We initially focused on expression of PcG proteins
belonging to the PRC1/HPC-HPH complex. Expression of
the BMI-1 binding partners, RING1, HPH1, HPC2, and
MEL-18, was found as strong nuclear staining in virtually
all H/RS cells in HL (Table 2, Figure 1). The HPC1 PcG
protein, however, was undetectable by immunohisto-
Table 2. Expression of PcG Genes in Hodgkin’s Lymphoma and HL-Derived Cell Lines
PcG gene
Hodgkin lymphoma
RS cells (n  54)
Hodgkin lymphoma reactive
lymphocytes (n  54)
HL cell lines*
(n  2)
BMI-1 54/54 54/54 (30–80% positive cells) Positive
HPH1 54/54 54/54 (30–80% positive cells) Positive
HPC1 7/54** 0/54 Positive
HPC2 54/54 54/54 (30–80% positive cells) Positive
RING1 54/54 54/54 (30–80% positive cells) Positive
MEL-18 54/54 8/54 (5% positive cells) Positive
46/54 (90% positive cells)
EZH2 54/54 54/54 (5% positive cells) Positive
EED 54/54 54/54 (5% positive cells) Positive
YY1 52/54† 54/54 (95% positive cells) Positive
CtBP 53/54‡ 54/54 (95% positive cells) Positive
*Expression of PcG proteins was investigated in HL-derived cell lines L428 and L1236.
**HPC1 expression in neoplastic H/RS cells is only observed using immunofluorescence on frozen tissue sections (7 individual cases were studied).
In paraffin-embedded HL tissue, HPC1 is not detected, most likely due to low expression in tumor cells.
†In 2 of 54 cases YY1 expression was absent from the neoplastic H/RS cells but present in the reactive lymphocytes.
‡In 1 of 54 cases CtBP expression was absent from the neoplastic H/RS cells but present in the reactive lymphocytes. CtBP-/YY1- cases were not
observed.
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chemistry in H/RS cells, although it can be part of the
HPC-HPH complex and binds to BMI-1. Finally, the non-
PcG transcriptional repressor CtBP that interacts with the
HPC2 PcG protein, was detectable in the majority of H/RS
cells examined in 53 of 54 cases of HL. These results
collectively show that virtually all of the PRC1/HPC-HPH
PcG complex core proteins are expressed by H/RS cells.
Our previous work on PcG expression in neoplastic
cells of HL demonstrated that H/RS cells express BMI-1
in combination with EZH2, belonging to the PRC2/EED-
EZH complex and normally present only in cycling B
cells.9 We therefore examined whether other components
of this complex are also present in H/RS cells. Immuno-
histochemical staining for EZH2, EED, and YY1 revealed
strong nuclear expression of these proteins in the nuclei
of virtually all H/RS cells (Table 2, Figure 1). In two in-
stances, YY1 was undetectable in H/RS cells whereas
lymphocytes in the surrounding infiltrate stained for this
protein. The expression patterns of EZH2, EED, and YY1
confirm the presence of EZH2 in H/RS cells and show
widespread expression of its binding partner EED in
combination with YY1.
PcG Expression in Reactive Lymphocytes in
Hodgkin’s Disease
Variable numbers of reactive lymphocytes, but always
more than 50%, expressed PcG proteins belonging to the
PRC1/HPC-HPH complex. BMI-1 and its binding partners
RING1, HPH1, and HPC2, displayed a similar staining
pattern, both in numbers of positive cells as well as
intensity of staining (Figure 1). Expression of HPC1, how-
ever, was never detected in reactive lymphocytes. Inter-
estingly, MEL-18 expression in H/RS cells was always
strongly positive, whereas in 8 of 54 cases (15%), only a
small number of reactive lymphocytes stained positive (
50% of the total number of lymphocytes). In the remaining
cases, expression of MEL-18 in reactive lymphocytes
was found in virtually every cell. Expression of EZH2 and
its binding partner EED on the other hand, was rarely
detected in reactive infiltrating lymphocytes. The third
PcG protein associated with the PRC2/EED-EZH com-
plex, YY1, was found in virtually all of the reactive lym-
phocytes in all HL cases tested.
Co-Expression of PcG Complexes PRC2/
EED-EZH and PRC1/HPC-HPH in Relation with
Proliferation State of H/RS Cells
PcG expression profiles were further explored by double
and triple immunofluorescence to gain insight in the
(co-)expression of both PcG complexes in relation with
cell cycle as determined by Ki67 expression in H/RS
cells. Multiple combinations of primary antibodies were
applied and co-expression was evaluated by confocal
laserscan microscopy. The combinations of primary an-
tibodies chosen included PcG proteins derived from both
PRC1/HPC-HPH and the PRC2/EED-EZH complex in
combination with Ki67 (Table 3).
H/RS cells are, in most instances, cycling cells ex-
pressing Ki67 and EZH2, and we therefore first per-
formed triple immunofluorescent staining for Ki67 and
EZH2 in combination with another PcG protein. We were
unable to examine expression of the EZH2 binding part-
ner EED in relation to Ki67, because antisera recognizing
these proteins are both of IgG1 subtype. In agreement
with our earlier findings, staining for BMI-1 and EZH2
clearly showed co-expression of these proteins in the
nuclei of cycling neoplastic Ki67POS H/RS cells (Figure
2A). Normal reactive lymphocytes in the surrounding in-
filtrate were primarily Ki67NEG resting cells, expressing
BMI-1 in the absence of EZH2 (Figure 2A). As previously
shown,9,46 we occasionally observed dividing Ki67POS
reactive cells, which expressed EZH2 but lacked BMI-1.
Investigation of BMI-1 and EZH2 binding partners by
triple immunofluorence (Table 3) confirmed the staining
patterns obtained by immunohistochemistry. Represen-
Figure 1. Immunohistochemical detection of PcG expression in H/RS cells. Neoplastic cells in HL express various members of the PRC1/HPC-HPH PcG complex
(BMI-1, MEL-18, RING1, HPH1, HPC2, and CtBP) and the PRC2/EED-EZH complex (EED, EZH2, and YY1). HPC1, a member of the PRC1/HPH-HPC PcG complex,
was undetectable in H/RS cells by immunohistochemistry.
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tative examples are shown in Figures 2 and 3. Staining for
BMI-1 in combination with HPC2, HPH1, and RING1 re-
vealed that these PcG proteins were co-expressed in the
nuclei of large dividing Ki67POS H/RS cells and in resting
Ki67NEG cells of the reactive infiltrate. A representative
example of triple immunofluorescent staining for BMI-1 in
combination with HPH1 and Ki67 is shown in Figure 2B.
In contrast to the results obtained by immunohistochem-
istry, the HPC1 PcG protein was clearly detectable in
neoplastic cells of HL by triple immunofluorescence (Ta-
ble 3). This is illustrated by triple staining for BMI-1 in
combination with HPC1 and EED in Figure 3B. Detection
of HPC1 by immunofluorescence suggests low level
HPC1 expression in the nuclei of malignant cells, be-
cause immunofluorescence on frozen sections is gener-
ally more sensitive than immunohistochemistry. We did
not observe expression of HPC1 in normal reactive lym-
phocytes. Finally, a combination of EZH2, BMI-1, and
EED showed that EZH2 and its binding partner EED are
expressed in the nuclei of the malignant cells in combi-
nation with BMI-1, which does not bind EZH2 nor EED
and is part of another PcG complex.
Table 3. Combinations of Antibodies Used for Double/Triple
Immunofluorescence on Hodgkin’s Lymphoma
Green
fluorescence*
Red
fluorescence†
Blue
fluorescence‡
Coexpression
in H/RS cells
HPC1 BMI-1 Ki67 Yes
HPC2 BMI-1 Ki67 Yes
HPH1 BMI-1 Ki67 Yes
RING1 BMI-1 Ki67 Yes
EZH2 BMI-1 Ki67 Yes
CtBP BMI-1 Ki67 Yes
MEL-18 BMI-1 Yes
HPC1 BMI-1 EED Yes
HPC2 BMI-1 EED Yes
HPH1 BMI-1 EED Yes
RING1 BMI-1 EED Yes
EZH2 BMI-1 EED Yes
CtBP BMI-1 EED Yes
MEL-18 Ki67 Yes
*Polyclonal rabbit-derived antibodies were visualized using an
ALEXA 488-conjugated goat-anti-rabbit antiserum.
†Antibodies with an IgG2b subtype were visualized with an HRP-
conjugated goat-anti-mouse IgG2b specific antibody followed by
rhodamine/tyramine intensification.
‡Antibodies if IgG1 or IgG2a subtype were detected by a biotinylated
goat-anti-mouse IgG1 or IgG2a followed by allophycocyanin-coupled
streptavidine.
Figure 2. Immunofluorescent detection of BMI-1 in combination with EZH2 and HPH1 in Ki67POS H/RS cells. A: Triple immunofluorescence staining for BMI-1
(red signal), EZH2 (green signal), and Ki67 (blue signal). Large Ki67POS H/RS cells co-express BMI-1 and EZH2 (arrow) whereas BMI-1- and EZH2 expression
are separated in healthy infiltrating cells (x denotes a resting (Ki67NEG) BMI-1POS/EZH2NEG cell; * denotes a dividing (Ki67POS) BMI-1NEG/EZH2POS cell). Lower
panel: detail of a single H/RS cell, showing single fluorescence signals (upper left and right, and lower left) and the combination of these signals (lower right).
B: Triple immunofluorescence staining for BMI-1(red signal), HPH1 (green signal), and Ki67 (blue signal). Large Ki67POS H/RS cells co-express BMI-1 and HPH1
(arrow) whereas dividing healthy infiltrating cells do not express BMI-1 and HPH1 (x). By contrast, BMI-1 and HPH1 are detectable in resting Ki67NEG healthy
infiltrating cells (*). Lower panel: as in A.
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In summary, proliferating neoplastic H/RS cells co-
express PcG core proteins derived from the PRC1/HPC-
HPH and the PRC2/EED-EZH complex. The expression
pattern of these proteins, BMI-1 in combination with
RING1, HPH1, and HPC2, versus EZH2 in combination
with EED, is always exclusive in reactive lymphocytes. In
addition, H-RS cells express low levels of HPC1, which is
undetectable in healthy reactive lymphocytes.
High Levels of BMI-1 Are Not Associated with
p16 Down-Regulation
Mouse experimental model systems demonstrated that
altered expression of PcG genes has strong effects on
regulation of the cell cycle. For instance, overexpression of
Bmi-1 in mice leads to down-regulation of p16INK4a and
subsequent induction of lymphoproliferation and develop-
ment of lymphomas.40–42 Therefore, the p16 gene appears
to be a downstream target of Bmi-1. Given the expression
of BMI-1 in H/RS cells, we questioned whether the presence
of BMI-1 in neoplastic cells is associated with absence of
p16INK4a. We found that p16INK4a expression was detected
as nuclear staining in the H/RS cells of 27 of 52 (52%) cases
(Figure 4), which were all BMI-1POS. As an internal positive
control, few scattered reactive lymphocytes stained.
This demonstrates that expression of BMI-1 in H/RS cells is
not necessarily associated with absence of p16INK4a
expression.
PcG Expression in HL-Derived Cell Lines L428
and L1236
Cytospin preparations were made from HL-derived cell
lines L428 and L1236 and PcG expression was deter-
Figure 3. Immunofluorescent detection of BMI-1 and EED in combination with HPC1 and EZH2. BMI-1 was detected by a red signal, EED by a blue signal, and
HPC1 and EZH2 by a green signal. A: Expression of the BMI-1 binding partner HPC1 in combination with EZH2 and EED. B: Large EZH2POS tumor cells express
the EZH2 binding partner EED in combination with BMI-1, which does not bind to EZH2 and is part of another PcG complex.
Figure 4. Immunohistochemical detection of p16INK4a on two cases of nod-
ular sclerosing HL. Two representative cases for p16INK4a positive and neg-
ative cases of HL in A and B, respectively
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mined using immunohistochemistry. The PcG staining
pattern of these cell lines closely resembled the expres-
sion pattern of neoplastic H/RS cells in patient material.
Both L428 and L1236 expressed all investigated proteins
of the PRC1/HPC-HPH complex, including BMI-1, MEL-
18, RING1, HPH1, and HPC1/2. In addition, these PRC1/
HPC-HPH complex proteins were co-expressed with the
EED, EZH2, and YY1 proteins of the PRC2/EED-EZH
complex.
Discussion
Classical H/RS cells originate from follicular B cells in the
germinal center.2–4 One group of genes that may con-
tribute to malignant transformation and development of
HL, belongs to the Polycomb-group (PcG).9 PcG proteins
are responsible for preservation of cell identity, and con-
tribute to regulation of lymphoid development at all
stages of hematopoiesis.10,12,16,17 We recently showed
that healthy follicular B cells in germinal centers display a
mutually exclusive expression pattern of PcG genes en-
coding the PRC1/HPC-HPH- and PRC2/EED-EZH PcG
complexes.45,46 Resting Ki67NEG mantle cells and cen-
trocytes preferentially expressed the PRC1/HPC-HPH
BMI-1 and RING1 PcG genes, whereas dividing Ki67POS
centroblasts were associated with detection of the PRC2/
EED-EZH proteins EED and EZH2. Interestingly, from
experiments in mutant mice it was concluded that core
proteins of the two complexes have opposing functions.
For instance, enhanced lymphoid proliferation was ob-
served in transgenic mice overexpressing Bmi-1,40–42
and in knockout mice with diminished expression of
Eed.44 These observations collectively suggest that a
balance between the different PcG complexes is critical
for normal division of hematopoietic cells.
In the current study and in our previous work,9 we
demonstrated that this balance is lost in neoplastic H/RS
cells and HL-derived cell lines. This is best illustrated by
the expression pattern of BMI-1 and its binding partners.
BMI-1 is not detected in healthy dividing EZH2POS B
cells, whereas H/RS cells and HL-derived cell lines co-
express BMI-1 and EZH2 (this study, and9,45,46). This
expression pattern suggests abnormal expression of
BMI-1 in transformed cells, and is in line with experimen-
tal model systems.40 The fact that BMI-1 functions as part
of a multiprotein complex, raises the question whether the
presence of BMI-1 in neoplastic cells is functionally rel-
evant. One condition that should be met is that the bind-
ing partners of BMI-1 are also present in the nucleus. In
the current study we showed that H/RS cells and HL-
derived cell lines display a highly conserved PcG expres-
sion profile of the core proteins that form the PRC1/HPC-
HPH- and PRC2/EED-EZH PcG complexes. In all
instances, BMI-1 was expressed in combination with its
binding partners RING1, HPH1, HPC1/2, and MEL-18. In
addition, various proteins constituting the PRC2/EED-
EZH complex, including EZH2, EED, and YY1 were also
expressed in the same nuclei. These data suggest that
both PcG complexes can be assembled in neoplastic
H-RS cells at the same time.
Three conclusions can be drawn from the available
expression data: firstly, H/RS cells display abnormal ex-
pression of PRC1/HPC-HPH proteins. This is best illus-
trated by the expression of BMI-1 and its binding part-
ners, because normal dividing B lymphocytes do not
express BMI-1 in combination with MEL-18, RING1,
HPH1, and HPC proteins (this study, and van Galen et al,
manuscript submitted). Secondly, expression of this set
of PRC1/HPC-HPH PcG genes in combination with the
PRC2/EED-EZH complex indicates an additional pattern
of abnormal PcG expression, because mature lympho-
cytes in germinal centers express core proteins of PRC1/
HPC-HPH- and PRC2/EED-EZH complexes in a mutually
exclusive pattern. Finally, if the PcG proteins that are
present in H-RS cells associate to form PcG complexes,
we suggest that this will result in formation of a different
PRC1/HPC-HPH complex than the one seen in healthy
resting B cells. The main difference in complex compo-
sition would most likely be related to low-level expression
of HPC1 in the nuclei of H/RS cells, because this PcG
protein is absent from healthy mature cells in the reactive
infiltrate. Whether PRC1/HPC-HPH and PRC2/EED-EZH
complexes actually bind to their target genes in tumor
cells cannot be determined by this type of study, but we
showed that various PcG proteins with DNA-binding ac-
tivity, such as MEL-1852 and YY1,53,54 are present in the
H/RS cells. We propose that abnormal PcG expression in
H/RS cells results in altered composition of the PRC1/
HPC-HPH PcG complex, and that this contributes to in-
terference with normal gene silencing patterns in H-RS
cells and loss of cell identity.
A causative relationship between abnormal expression
of PcG genes, altered gene silencing patterns, and loss
of cell identity is supported by various experimental
model systems. The best-known example is the Bmi-1
transgenic mouse, which identified Bmi-1 as an onco-
gene capable of down-regulating the cell cycle-associ-
ated proteins p16INK4a and p19ARF.41,42 In non-proliferat-
ing cells, p16INK4a and p19ARF specifically bind to the
cdk4/6 protein complex, thereby preventing cyclin D ac-
tivation and subsequent transition toward the S-phase.
Bmi-1-mediated down-regulation of p16INK4a induces
high levels of proliferating hematopoietic cells and forma-
tion of lymphomas. The inverse correlation between
Bmi-1 and p16INK4a expression in mouse lymphocytes
naturally leads to the question whether human p16INK4a is
also a downstream target of BMI-1. As reported in other
studies,55 we found that p16INK4a is undetectable in a
large number of HL cases. Although loss of p16INK4a
expression in malignant lymphomas is usually associated
with altered methylation patterns or deletion of the
gene,55,56 it is formally possible that BMI-1 overexpres-
sion is an additional contributing factor. However, our
data show that expression of BMI-1 in H/RS tumor cells is
not necessarily related to p16INK4a down-regulation, be-
cause more than half of the HL cases expressed BMI-1 in
combination with p16INK4a. Although this suggests that
human p16INK4a may not be regulated by BMI-1, these
results should be interpreted with caution because reg-
ulation of individual target genes of Bmi-1 may be cell
type-specific.57 Indeed, recent studies of lung and penile
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carcinomas58,59 reported an inverse correlation between
the presence of BMI-1 and the absence of p16INK4a. It is
theoretically possible that an effect of BMI-1 on p16INK4a
in neoplastic cells of HL may be masked by the expres-
sion of other PcG genes. Several of these are associated
with malignant transformation through mechanisms that
do not involve p16INK4a. Enhanced expression of RING-1,
for instance, resulted in oncogenic transformation and
up-regulation of proto-oncogenes c-jun and c-fos,22 but
Mel-18 seems to function as a tumor suppressor gene in
the mouse.52 A further complication is that several PcG
genes detected in H/RS cells, such as HPC2, are nor-
mally expressed by proliferating B cells (this study, and
van Galen et al, submitted). However, it is unclear
whether the level of HPC2 expression is altered in tumor
cells. This is an important issue to resolve because inter-
ference with the expression or function of HPC2 is asso-
ciated with abnormal cell cycle regulation.43 In addition,
enhanced expression of EZH2 was recently associated
with mantle-cell lymphomas48 and progression of pros-
tate and breast tumors,60–62 suggesting that this PcG
gene may also contribute to development of neoplastic
H/RS cells.
Concluding Remarks
The importance of PcG proteins in maintenance of cell
identity is underscored by the relationship between ab-
normal expression of PcG genes and malignant transfor-
mation in experimental model systems. In the current
study we demonstrated that neoplastic cells in HL abnor-
mally express multiple PcG genes. Although this sug-
gests that the individual regulation of several PcG genes
is disturbed, it is also possible that a regulatory mecha-
nism shared by multiple PcG genes is affected. A poten-
tial application of the observed PcG expression patterns
in HL is improved diagnostics. For instance, expression
of HPC1 by H-RS cells may possibly be used to distin-
guish HL from CD30 ALCL. Preliminary results of PcG
expression patterns in T-NHL showed that CD30 ALCL
are HPC1 negative (van Galen et al, in preparation), but
this finding needs to be confirmed in a larger patient
population. We propose that abnormal PcG expression in
HL results in an altered composition of the PRC1/HPC-
HPH PcG complex in H/RS cells, which probably affects
expression of target genes involved in regulation of ap-
optosis and/or the cell cycle. Our observations add to the
increasing evidence that PcG genes are important con-
tributors to development of hematological malignancies.
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Background : Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is highly variable and
poorly predictable. Microarray studies showed that patients with DLBCL with a germinal centre B cell-like
(GCB) phenotype have a better prognosis than those with an activated B cell-like (ABC) phenotype. The BMI1
proto-oncogene was identified as one of the genes present in the signature of the ABC type of DLBCL,
associated with a poor prognosis.
Objectives : (1) To investigate, in primary nodal DLBCL, the expression of BMI1 and its association with
clinical outcome and DLBCL signature; (2) to look for an association between BMI1 expression and the
expression of its putative downstream targets p14ARF and p16INK4a.
Results : BMI1 expression was found to be associated with poor clinical outcome, but not clearly with an ABC-
like phenotype of DLBCL. Expression of BMI1 was frequently, but not always, related to low levels of
expression of p14ARF and p16INK4a.
Conclusion : Expression of BMI1 is associated with an unfavourable clinical outcome of primary nodal DLBCL.
D
iffuse large B cell lymphomas (DLBCL) are heterogeneous
in terms of clinical behaviour, histological features and
differences in response to treatment. Currently, the
clinical parameters comprised in the International Prognostic
Index are used as a prognostic indicator in DLBCL.1 Also,
various cellular and molecular factors that have prognostic
significance in DLBCL have been identified.2–9
Neoplastic cells in DLBCL cases originate from germinal
centre B (GCB) cells or their descendents.10 Recent studies
based on microarray analysis showed that part of DLBCL
phenotypically resemble non-neoplastic GCB cells, but that part
of DLBCL show an expression profile more consistent with an
activated B cell (ABC)-like phenotype.11 12 Furthermore, DLBCL
with a GCB-like phenotype have a considerably better prognosis
than DLBCL with an ABC-like phenotype.4 BMI1 was identified
as one of the genes that distinguish the GCB-like from ABC-like
DLBCL (supplement of studies by Alizadeh et al11 and de Boer
et al13), with high expression levels in ABC-like DLBCL.
BMI1 belongs to the Polycomb group of genes that are
important regulators of mammalian lymphopoiesis (reviewed
in Raaphorst et al14) Furthermore, BMI1 has been shown to be
essential for self-renewal of haematopoietic and neural stem
cells, in part through inhibition of genes regulating senes-
cence.15 Initially, BMI1 was identified as a proto-oncogene in
the development of lymphomas.16 Further studies showed that
overexpression of BMI1 in transgenic mice results in down
regulation of the cell cycle inhibitors p19ARF and p16INK4a, and
that BMI1 cooperates with c-Myc in tumorigenesis by inhibiting
c-Myc-induced apoptosis through p14ARF.15 17 18
p14ARF and p16INK4a are alternatively spliced products from
the INK4a/ARF (CDKN2A) locus, with no structural homology.
p14ARF is involved in the induction of apoptosis via p53,
whereas p16INK4a is involved in the inhibition of cell cycle
progression through cyclin D1 and CDK4/6.19 Both these
processes can be controlled by BMI1 via the INK4a/ARF
locus.20 21
In non-neoplastic lymphoid tissues, BMI1 is primarily
expressed in resting cells. In follicle center B cells, the non-
neoplastic counterpart of at least part of DLBCL, BMI1, was
mainly expressed in centrocytes, but not in dividing centro-
blasts.22 This was in contrast with aggressive B cell lymphomas
in which we have previously observed that BMI1 is frequently
expressed in dividing neoplastic cells, suggesting that aberrant
Polycomb group expression contributes to malignant transfor-
mation in these lymphomas.23 24 We also showed that BMI1
is preferentially expressed in aggressive B cell lymphomas
(DLBCL, Burkitt’s lymphomas and mantle cell lymphomas),
and not in indolent lymphomas (follicular and small
lymphocytic lymphomas).23 However, in this study we did
not investigate whether BMI1 expression predicts clinical
outcome.
Thus, BMI1 is a proto-oncogene that, when aberrantly
expressed in mice, is involved in the pathogenesis of
lymphomas, possibly by disruption of the p14ARF and/or by
p16INK4a regulated pathways.24 25 Furthermore, inhibition of
apoptosis by disruption of the p14ARF pathway may result in
reduced sensitivity to chemotherapy-induced cell death and
poor outcome in patients with BMI1-positive lymphomas.
Therefore, we investigated in primary nodal DLBCL with
extensive follow-up whether BMI1 expression indeed correlates
with an ABC-like phenotype and whether expression of BMI1
predicts poor clinical outcome. Furthermore, to get insight into
the possible pathogenic function of BMI1, we investigated
whether expression of BMI1 is related to decreased levels of
p14ARF and/or p16INK4a expression.
MATERIALS AND METHODS
Clinical material
Selection of formalin-fixed, paraffin wax-embedded tissue
blocks of 60 biopsy specimens of primary nodal DLBCL and
the clinical data of these patients were described previously.8
Table 1 summarises the patient characteristics. Most patients
(n=60) received polychemotherapy, consisting of CHOP
(cyclophosphamide, doxorubicin, vincristine, prednisone) regi-
mens or variants, either alone (n=31) or in combination with
Abbreviations: ABC, activated B cell; DLBCL, diffuse large B cell
lymphomas; GCB, germinal centre B cells
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involved field radiation (n=24); in five cases, only involved
field radiation was given. The institutional review board of the
VU Medical Centre (Amsterdam, The Netherlands) approved
the study. Informed consent was provided according to the
Declaration of Helsinki.
Antibodies used in this study
Monoclonal BMI1 antibody (clone 6C9) was generated pre-
viously,26 polyclonal p14ARF was obtained from Abcam,
Cambridge, UK, and monoclonal p16Ink4a (clone E6H4) was
a kind gift from Dr R Ridder. Specificity of these antibodies was
determined by western blot analysis and bands were found at
the predicted height (not shown).
Immunohistochemistry
Slides of paraffin wax-embedded biopsy specimens were used
for the detection of BMI1, p14ARF and p16INK4a. Sections were
deparaffinised with xylene, endogenous peroxidase was
blocked, and antigens were retrieved in either citrate buffer
(10 mmol/l, pH 6.0) or TRIS/EDTA buffer (10 mmol/l/1 mmol/l,
pH 9.0) in either microwave or autoclave.
Methods for detection of BMI1 were described previously.22
For p14ARF and p16INK4a detection, slides were rinsed in
phosphate-buffered saline and primary antibody was applied at
optimal dilution. After 1 h at room temperature (20 C˚), slides
were incubated with highly sensitive EnVison horseradish
peroxidase system (Dako, Glostrup, Denmark). Bound anti-
bodies were visualised by incubation with diaminobenzidine/
H2O2. Slides were counterstained with haematoxylin.
Quantification of immunohistochemical staining
For all stainings, percentages of positive tumour cells were
evaluated semiquantitatively in approximately the same area;
scattered reactive lymphocytes served as an internal positive
control. Two observers analysed all stainings independently. In
case of disagreement, the staining results were reanalysed by
the observers until consensus was reached.
To determine cut-off levels with the most discriminative
power, cut-off was tested at 25%, 50% and 75% in relation to
prognosis; the statistically most significant cut-off (at 25% for
all stainings) was used in this study.
Phenotypic analysis of GCB-like DLBCL versus ABC-like
DLBCL
Previously, we divided cases in a GCB-like or an ABC-like
subtype,27 by an algorithm modified from the one previously
described by Hans et al4.
Statistical analysis
Survival time was measured from the time of initial diagnosis
until death with disease or until the end of follow-up. Patients
who died of causes unrelated to the disease were censored at
the time of death (n=2).
Survival curves were constructed with the Kaplan–Meier
method. Differences between the curves were analysed using
the log-rank test. Multivariate analysis was performed using
the Cox proportional hazards model.28 Qualitative variables
were analysed by Pearson x2 test or by the Fisher exact test,
where appropriate. The Kruskal–Wallis test to compare group
means and the Spearman test was used to test correlations
between different variables. All p values are based on two-tailed
statistical analysis, considering p values ,0.05 as significant.
Analyses were performed using SPSS V.10.1.
RESULTS
Aberrant expression of BMI1 in DLBCL as compared with
normal follicle centre cells
As described previously, BMI1 expression in non-neoplastic
germinal centres is almost completely restricted to non-dividing
cells.22 29 In DLBCL, BMI1 was detected in DLBCL in all patients,
but in highly varying percentages of dividing lymphoma cells.
The percentage of BMI1-positive tumour cells ranged from ,5%
to almost 100% (fig 1); 25% of the cases had ,25% whereas
75% had .25% BMI1-positive tumour cells.
Low levels of BMI1 expression are related to a
favourable clinical outcome
Using log-rank and Cox regression analysis, different
thresholds of percentages of BMI1-positive tumour cells were
tested; the threshold with optimal discriminative power with
regard to overall survival was 25% (table 2, fig 2A). Using
multivariate analysis including GCB/ABC phenotype and BMI1
expression as categorical variables did not yield additional
significant prognostic value for expression of BMI1 above GCB
versus ABC phenotype (fig 2B,C). However, expression of
BMI1 tended to be related to poor outcome, especially in GCB-
like DLBCL (90% 5-year overall survival time v 55% 5-year
overall survival time for BMI1 negative and positive cases,
respectively).
BMI1 expression is not restricted to activated B cell-l ike
DLBCL
Microarray studies have shown that BMI1 is one of the
genes that distinguishes a GCB-like DLBCL from an ABC-like
DLBCL. Using immunohistochemical analysis, cases with
many BMI1 positive tumour cells more often showed an ABC-
like phenotype, although this relation was not significant
(table 3).
Aberrant expression of p16INK4a and p14ARF in DLBCL
as compared with normal follicle centre cells
To determine whether BMI1 expression is related to (lowered)
p14ARF or p16INK4a expression, we subsequently investigated
p14ARF and p16INK4a expression in normal lymphoid tissue
and DLBCL cases. In non-neoplastic lymphoid tissue p14ARF
and p16INK4a are expressed in a limited number of cells of the
Table 1 Patient characteristics obtained by univariate
survival analysis
Patient
characteristics Number
Deaths with
lymphoma
5-Year
survival* p Value
IPI`
1 16 5 58 NS
2 21 12 44
3 14 7 43
4 8 6 0
B symptoms
Yes 19 13 32 0.02
No 41 18 52
Stage`
1+2 25 8 63 0.03
3+4 34 22 34
ABC/GCB profile1
GCB 22 8 59 0.06
ABC 36 22 38
ABC, activated B cell; GCB, germinal centre B cells; IPI, International
Prognostic Index.
*As estimated from the Kaplan–Meier curves.
As determined by x2 test, unless stated otherwise.
`Data concerning stage and therefore IPI could not be retrieved in one
patient.
1Data concerning the ABC/GCB profile could not be retrieved in two
patients.
60
germinal centre (fig 1). Nuclear expression of p16INK4a was
found mainly in centroblasts. Interestingly, cytoplasmic p14ARF
expression was also detected in sporadic interfollicular cells
with apoptotic characteristics, consistent with its apoptosis-
inducing function.20
In contrast, in p14ARF and p16INK4a positive tumours,
expression was observed in the nucleus and cytoplasm of most
neoplastic cells of DLBCL. In addition, in DLBCL, p14ARF-
positive cells did not show apoptotic characteristics (fig 1).
Expression of BMI1 in DLBCL is not consistently related
to low levels of p16INK4a or p14ARF expression
Expression of p14ARF and p16INK4a was detected as nuclear
staining in the tumour cells in 21 of 42 and in 22 of 59 cases,
respectively. Expression of p14ARF and p16INK4a showed no
direct correlation with expression of BMI1. However, p16INK4a
tended to be more frequently absent in cases with many BMI1-
positive tumour cells: 29 of 43 patients with high numbers of
BMI1-positive tumour cells showed no expression of p16INK4a
BMI1 p14ARF p16INK4a
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Figure 1 Expression of BMI1, p14ARF and p16INK4a in non-neoplastic lymphoid tissue and in three primary nodular DLBCL. (A–C) hyperplastic lymphoid
tissue. BMI1 staining is observed in resting mantle zone cells, centrocytes and T cells including germinal centre T cells, but not in centroblasts.29 p14ARF and
p16INK4a expression is detectable only in sporadic cells. Some of the p14ARF-positive cells show morphological features of apoptosis (fig B insets). (D–L)
BMI1, p14ARF and p16INK4a staining patterns in three different DLBCL cases. DLBCL #1: this case shows BMI1-positive staining in .25% of tumour cells,
but no expression of p14ARF and p16INK4a. DLBCL #2: expression of p14ARF is observed in the absence of BMI1 and p16INK4A expression. DLBCL #3:
this case shows expression of BMI1, p14ARF and p16INK4a.
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as compared with 8 of 16 patients with few BMI1-positive
tumour cells (p=0.24; not shown). Also, when the analysis
was restricted to cases without a proven genetic loss in the
CDKN2A locus as determined by CGH analysis (n=27;
Oudejans JJ et al, manuscript in preparation), no correlation
between expression of p14ARF and p16INK4a, and BMI1 was
observed (table 3).
DISCUSSION
In this study, we have shown that BMI1 and its presumed target
genes p14ARF and p16INK4a are frequently aberrantly expressed
in malignant cells of DLBCL when compared with normal
follicle centre B-lymphocytes, and that expression of BMI1 is
related to an unfavourable clinical outcome in primary nodal
DLBCL.
It was previously shown and confirmed by us that DLBCL
with an ABC-like phenotype have a relatively unfavourable
clinical outcome and that one of the genes involved in the
designation of this profile is BMI14 (supplement of studies by
Alizadeh et al11, de Boer et al13 and Muris et al27). Although we
found that BMI1 expression is indeed more frequently present
in ABC-like DLBCL, BMI1 expression was not restricted to this
group of DLBCL. This might be explained by the fact that, also
in the microarray study, BMI1 alone does not determine the
GCB-like versus ABC-like phenotype.11 13 Expression of BMI1
was also not significantly correlated with expression of MUM-1
(data not shown), which was previously shown to be related to
a poor prognosis.27 This indicates that the prognostic effect of
BMI1 expression is probably not directly related to MUM-1
expression.
A possible explanation for the observed relationship between
BMI1 expression and prognosis is that BMI1 inhibits apoptosis
via down regulation of the p14ARF gene. Experimental model
Table 2 Patient characteristics in relation to BMI1
expression
Patient characteristics
% BMI1-positive tumour cells
p Value*,25% (n = 15) >25% (n = 45)
Median age (range) 62.3 (24–94) 63 (34–94) NS
Sex
M 12 27 NS
F 3 18
Stage`
1+2 5 20 NS
3+4 10 24
B symptoms
Yes 5 14 NS
No 10 31
IPI1
1+2 8 29 NS
3+4 7 15
Complete remission
Yes 13 29 NS
No 2 16
Relapse
Yes 4 9 NS
No 9 20
Death
Yes 4 27 0.04
No 11 18
F, female; IPI, International Prognostic Index; M, male.
*As determined by x2 test, unless stated otherwise.
As determined by Mann–Whitney U test.
`Data concerning the staging could not be retrieved in one case.
1Data concerning IPI could not be retrieved in one case.
These cases involve patients who did reach complete remission.
1.0
0.8
0.6
0.4
0.2
0.0
C
um
ul
at
iv
e 
su
rv
iv
al
0 12 24 36 48 60
Overall survival time (months)
n = 60, p = 0.04
BMI1 high: n = 45, 27 deaths
BMI1 low: n = 15, 4 deaths
1.0
0.8
0.6
0.4
0.2
0.0
C
um
ul
at
iv
e 
su
rv
iv
al
0 12 24 36 48 60
Overall survival time (months)
n = 31, p = 0.35
BMI1 high: n = 26, 18 deaths
BMI1 low: n = 5, 2 deaths
1.0
0.8
0.6
0.4
0.2
0.0
C
um
ul
at
iv
e 
su
rv
iv
al
0 12 24 36 48 60
Overall survival time (months)
n = 28, p = 0.15
BMI1 high: n = 19, 8 deaths
BMI1 low: n = 9, 1 death
A
B
C
Figure 2 Comparison of overall survival in patients with primary nodal
DLBCL according to BMI1 expression. High numbers of BMI1-positive
tumour cells are correlated with poor prognosis (A). BMI1 expression has
no additional significant prognostic value above GCB (B) versus ABC (C)
phenotype.
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systems demonstrated that BMI1 cooperates with c-Myc to
induce lymphomas by preventing c-Myc and Ink4a/ARF induced
apoptosis,18 thus inhibiting the intrinsic apoptosis pathway and
thereby explaining poor response to chemotherapy. However,
inhibition of apoptosis by high expression of BMI1 would imply
down regulation of p14ARF, which was observed only in some
BMI1-positive cases. In non-neoplastic lymphoid tissues,
expression of p14ARF in reactive lymph nodes was observed
in a few cells frequently, with morphological features of
apoptosis (see fig 1). This would be consistent with the normal
tumour-suppressive, apoptosis-inducing function of p14ARF.
However, in p14ARF-positive DLBCL, diffuse positive staining
was observed in cells without morphological features of
apoptosis, suggesting that the normal apoptosis-inducing effect
of p14ARF is disrupted, consistent with a previous paper by
Sanchez-Aguilera et al.30 Thus, in some cases, p14ARF is
expressed despite expression of BMI1, but its apoptosis-
inducing effect might be counteracted by downstream apopto-
sis-inhibiting proteins like Bcl-2 and XIAP.
Alternatively, BMI1 could be involved in down regulation of
the tumour suppressor protein p16INK4a, resulting in suppres-
sion of senescence and cell cycle control,15 causing enhanced
proliferation of the tumour cells. Indeed, in our study we also
found BMI1-positive cases that showed absence or low levels of
p16INK4a expression. However, some BMI1-positive patients
also showed expression of p16INK4a in most rapidly proliferat-
ing cells. Similar to p14ARF, expression of p16INK4a in non-
neoplastic reactive lymphoid tissues is restricted to very few
follicle centre cells. Thus, the normal cell cycle suppressive
function of p16INK4a in these lymphomas is probably dis-
rupted. Co-expression of BMI1 and p14ARF/p16INK4a may be
explained by phosphorylation of BMI1 and subsequent de-
repression of the INK4a/ARF locus, as recently shown by
Voncken et al31
Recently, Glinsky et al32 also investigated the expression of
BMI1 and its putative targets in relation to prognosis.
Expression of these 11 BMI1 target genes was correlated to
poor prognosis in patients with lymphoma. Thus, BMI1 seems
to be an important gene in normal and neoplastic tissue,
because of its role in regulating the expression of various genes
involved in cell cycle control.
We conclude that BMI1 and p14ARF and p16INK4a are
aberrantly expressed in some primary nodal DLBCL. Expression
of BMI1 is related to unfavourable outcome. Down regulation of
tumour suppressor genes p14ARF and p16INK4a by BMI1 might
explain the relationship between BMI1 expression and poor
outcome in some DLBCL. However, strong expression of p14ARF
and p16INK4a in some DLBCL suggests that the tumour-
suppressive effect of these proteins is counteracted by down-
stream mechanisms.
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Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival
time in ABC-like primary nodal diffuse large B-cell lymphomas
Aims: Tumour necrosis factor (TNF)-receptor associ-
ated factor 2 (TRAF2) is an adaptor molecule involved
in nuclear factor (NF)-jB activation, which is charac-
teristic of in vitro activated B-cell (ABC)-like diffuse
large B-cell lymphomas (DLBCL) and may result in
expression of anti-apoptotic genes and poor response to
chemotherapy. TRAF2 also has direct anti-apoptotic
properties via interference with the apoptosis signalling
cascade. The aim was to determine whether TRAF2
is preferentially expressed in ABC-like DLBCL, and
whether expression correlates with clinical outcome.
Methods and results: TRAF2 was expressed in nine of 20
tested ABC-like DLBCLs and in only one of 13 tested
germinal centre B-lymphocyte (GCB)-like DLBCLs. High
TRAF2 expression was correlated with high Interna-
tional Prognostic Index at time of presentation, high
chance of relapse and short progression-free survival
time in 44 tested DLBCLs. Furthermore, when analysis
was restricted to ABC-like DLBCL only, TRAF2 expres-
sion was signiﬁcantly associated with poor progression-
free survival time.
Conclusions: TRAF2 might be involved in activation of
NF-jB in a subset of ABC-like DLBCL, and its expression
is associated with a particularly poor outcome in
primary nodal DLBCL patients. Because of its possible
effect on to chemotherapy resistance, resistance,
TRAF2 might be an attractive candidate as a molecular
target for TRAF2+ DLBCL.
Keywords: apoptosis, diffuse, large B-cell, lymphoma, TNF receptor-associated factor 2
Abbreviations: ABC, activated B cell; CHOP, cyclophosphamide, adriamycin, vincristine and prednisone; DD, death
domain; DISC, death-inducing signalling complex; DLBCL, diffuse large B-cell lymphoma; ER, endoplasmic
reticulum; GCB, germinal centre B lymphocyte; IKK, IjB kinase; IPI, International Prognostic Index; IRE, inositol-
requiring enzyme; NF, nuclear factor; PBS, phosphate-buffered saline; TNFR, tumour necrosis factor receptor;
TRAF, TNFR-associated factor
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common type of non-Hodgkin’s lymphoma. Despite
intensive chemotherapy, outcome will eventually be
fatal in approximately 30–40% of patients.1 The
addition of rituximab to cyclophosphamide, adriamy-
cin, vincristine and prednisone (CHOP) has improved
outcome considerably in these patients and has
recently become the standard form of treatment.2
Many studies have indicated that the intrinsic sensi-
tivity of lymphoma cells to undergo apoptosis is an
important determinant of response to chemotherapy
and eventual clinical outcome in the individual
patient.3,4 This notion has challenged many groups
to identify molecular determinants causing intrinsic
resistance to chemotherapy. Several microarray-based
Address for correspondence: C J L M Meijer, MD, PhD, Department
of Pathology, VU Medical Centre, De Boelelaan 1117, 1007 MB
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expression studies have independently identiﬁed two
major subtypes of DLBCL, one resembling non-neo-
plastic germinal centre B lymphocytes (GCB), the other
resembling activated B cells (ABC).5,6
Subsequent studies have demonstrated that ABC-like
DLBCLs are characterized by high expression levels
of genes that are under translational control of
the nuclear factor (NF)-jB signalling pathway. These
highly expressed NF-jB target genes include many
apoptosis-inhibiting genes. Because most chemothera-
peutic drugs used in the treatment of DLBCL primarily
induce cell death via induction of the stress-induced
apoptosis pathway,7–10 high expression levels of these
anti-apoptotic NF-jB target genes might explain che-
motherapy resistance and poor outcome in ABC-like
DLBCL.2,4
It remains unknown what mechanism(s) cause
constitutive activation of the NF-jB pathway in DLBCL.
Under physiological conditions the NF-jB pathway is,
depending on cellular context, activated by triggering
of various receptor-mediated pathways, including
tumour necrosis factor receptor (TNFR), CD40, B-cell
receptor and Toll-like receptor pathways.11 Two path-
ways downstream of these receptors have been iden-
tiﬁed: a canonical and non-canonical pathway.
Signalling by the canonical pathway relies on activa-
tion of certain IjB kinases (IKK) leading to phosphor-
ylation of IjB and resulting in the release of coupled
NF-jB dimers. Activation of IKK in the non-canonical
pathway leads to cleavage of NF-jB subunit p100 and
release of activated p50 subunits.12 Several of these
subunit dimers can induce the transcription of anti-
apoptotic factors such as Bcl-XL, FLIP, XIAP, cIAP1 and
cIAP2,11,13,14 which may explain the poor outcome in
ABC-like DLBCL.5,6,15
An important adaptor molecule that is involved in
NF-jB activation is TNFR-associated factor (TRAF)2.
TRAF2 is responsible for signal transduction in the
canonical NF-jB pathway, whereas it is believed to be a
negative regulator of the non-canonical pathway.16
TRAF2 is one of the TRAF proteins that associate with
cytoplasmic regions of TNFR superfamily members.
Thus far, six TRAF proteins, TRAF1 to TRAF6, have
been identiﬁed. Activation of TNF superfamily members
leads to recruitment of a deﬁned set of TRAFs and other
proteins to the receptors and transduces signals result-
ing in activation of the NF-jB, JNK, p38, ERK and PI3K
pathways.14,17,18
TRAF2 is particularly interesting, because it not only
induces expression of anti-apoptotic genes via activa-
tion of the NF-jB pathway, but it also has anti-
apoptotic properties itself.14,17,18 TRAF2 can recruit
TRAF1, cIAP1 and cIAP2 to the death-inducing
signalling complex (DISC), resulting in disruption of
pro-caspase 8 cleavage into active caspase 8, thus
resulting in inhibition of the extrinsic apoptosis path-
way.17,18
Furthermore, TRAF2 has recently been implicated in
the endoplasmic reticulum (ER) stress response result-
ing in apoptosis. ER stress can be caused by the
accumulation of unfolded proteins in the lumen of the
ER.19 Although still controversial, it appears that
TRAF2 inhibits caspase 12 cleavage and subsequent
apoptosis by binding of TRAF2 to inositol-requiring
enzyme (IRE) 120 and NF-jB activation takes
place.19,21–23 Thus, TRAF2 expression may result in
inhibition of both stress-induced apoptosis pathways
and in inhibition of the extrinsic pathway.
In this study, we investigated whether TRAF2 is
expressed in primary nodal DLBCL, whether TRAF2 is
expressed preferentially in ABC-like DLBCL and
whether TRAF2 expression is related to clinical out-
come.
Materials and methods
clinical material
Formalin ﬁxed parafﬁn-embedded tissue blocks of 44
previously untreated patients with primary nodal
DLBCL classiﬁed according to the 2001 World Health
Organization classiﬁcation24 were used in this study.
Cases were diagnosed between 1989 and 2003 and
were retrieved from the departments of Pathology of
the VU University Medical Centre Amsterdam, the
University Hospital Nijmegen, the Leiden University
Medical Centre and the Sint Antonius Hospital Nieu-
wegein (all the Netherlands). Patients included in this
study were treated according to standard primary
anthracycline-containing combination chemotherapy
(predominantly CHOP), either alone or in combination
with involved ﬁeld irradiation. The institutional review
board of the VU Medical Centre approved the study.
Informed consent was provided according to the
Declaration of Helsinki.25
immunohistochemical analysis of traf2
expression
Sections (3 lm thick) from the parafﬁn-embedded
tissue blocks were used for the detection of TRAF2
(clone 33A1293; Abcam, Cambridge, UK). Slides were
deparafﬁnized with xylene, endogenous peroxidase was
blocked and antigen retrieval was performed in citrate
buffer (10 mm, pH 6.0) by microwave. Slides were
rinsed in phosphate-buffered saline (PBS) and primary
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antibody was applied at a 200-fold dilution in
PBS. After 1 h incubation at room temperature, the
EnVison horseradish peroxidase system (Dako, Glost-
rup, Denmark) was applied. Bound antibodies were
visualized by incubation with diaminobenzidene ⁄ H2O2.
Slides were counterstained with haematoxylin. Per-
centages of TRAF2-expressing tumour cells were
scored semiquantitatively in steps of 10% from 0% to
100%.
gcb versus abc-l ike dlcbl
GCB or ABC-like phenotype was determined for 33
cases by microarray mRNA expression analysis on
frozen tissue as previously described.26 We performed
hierarchical cluster analysis of the genes included in
the DLBCL subgroup predictor for spotted cDNA
microarrays as recently described by Wright et al.27
Of the 27 genes included in the predictor, 21 were
present on our platform. Clustering using Pearson
correlation resulted in two separate DLBCL groups
corresponding to the GCB- and ABC-like DLBCL. A
third group was not clearly categorized in GCB- or
ABC-like DLBCL; this group probably reﬂects type 3
DLBCL.26 When type 3 DLBCL was included in the
ABC-like DLBCLs, a similar predictive value with regard
to clinical outcome was observed as in previous reports
(P = 0.07).5,26,28
statistical analysis
Progression-free survival time was measured from
initial diagnosis until occurrence of a relapse. Overall
survival time was measured from time of initial
diagnosis until death with or without disease, or until
end of follow-up. Survival curves were constructed
with the Kaplan–Meier method. Differences between
the curves were analysed using the log rank test.
Qualitative variables were analysed using the Pearson
chi-square test or Fisher’s exact test, when appropriate.
Analyses were performed using SPSS software (version
11.5; SPSS Inc., Chicago, IL, USA).
Results
traf2 is mainly expressed in abc-l ike dlbcl
In normal reactive lymphoid tissues TRAF2 expression
was observed as cytoplasmic immunoreactivity mainly
in interfollicular cells and in scattered centroblasts and
immunoblasts in the germinal centres (Figure 1A).
This pattern of reactivity was similar to that previously
reported by Zapata et al.29
In DLBCL biopsy specimens, major differences in
percentages of TRAF2-expressing tumour cells were
observed. If expression of TRAF2 in lymphoma cells
was observed, >20% of the lymphoma cells were
always immunopositive. Positivity was detected in 11
out of 44 tested DLBCLs (Figure 1B). TRAF2 protein
expression correlated with TRAF2 mRNA expression
levels, as determined by microarray analysis in 33
tested cases (P = 0.003, see Figure 2).
A signiﬁcant correlation was found between
TRAF2 protein expression and DLBCL cell of origin
expression proﬁle as determined by microarray anal-
ysis (see Table 1). Intense TRAF2 expression was
found in only one of 13 GCB-like DLBCL cases,
Figure 1. Immunohistochemical detection of TNFR-associated
factor (TRAF) 2 in non-neoplastic lymphoid tissue and in diffuse large
B-cell lymphoma (DLBCL). A, Strong cytoplasmic expression of
TRAF2 is observed in scattered interfollicular cells and in scattered
centroblasts and immunoblasts in hyperplastic lymphoid tissue.
B, In TRAF2+ DLBCL TRAF2 expression is also detected as
cytoplasmic reactivity in at least 20% of the neoplastic cells. In this
case all neoplastic cells were immunopositive.
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whereas half of the ABC-like DLBCL cases showed
TRAF2 expression.
traf2 express ion is correlated with short
progress ion-free survival time
High expression of TRAF2 was found to correlate with
a particularly poor progression-free survival time
(P = 0.001, see Figure 3A), all but one of the TRAF2+
cases relapsing within 3 years. Cases with high expres-
sion of TRAF2 also tended to have a relatively poor
overall survival time, although this observation was
not signiﬁcant (Figure 3B). Seven out of 10 TRAF2+
cases were high-risk patients according to the Interna-
tional Prognostic Index (IPI), as most of them presented
with high stage disease. Gender or B-symptoms (fever,
night sweats and weight loss) did not correlate with
TRAF2 expression (see Table 2).
Signiﬁcantly, when analysis was restricted to only
ABC-like DLBCL (as determined by microarray proﬁl-
ing), expression of TRAF2 was still signiﬁcantly asso-
ciated with poor progression-free survival time (see
Figure 3C), suggesting that TRAF2 is an independent
prognostic parameter in ABC-like DLBCL.
traf2 express ion correlates with high
numbers of activated cytotoxic
t lymphocytes
In our previous studies, using samples from the same
patients as used in this study, several apoptotic markers
were identiﬁed whose expression correlated with prog-
nosis.15,25 Only percentages of activated cytotoxic
T lymphocytes correlated with expression of TRAF2.
No correlation was observed with the other markers
(see Table 1).
Discussion
This study has shown that TRAF2 is predominantly
expressed in a proportion of ABC-like DLBCLs and
rarely in GCB-type B-cell lymphoma. Expression of
TRAF2 is associated with a high IPI at time of
presentation, a high chance of relapse and a short
Figure 2. Conﬁrmation of TNFR-associated factor (TRAF) 2 immuno-
histochemistry by microarray detection of TRAF2 mRNA levels.
Statistical analysis using the independent samples T-test showed a
signiﬁcant difference in TRAF2 mRNA levels between groups of
TRAF2) and TRAF2+ cases as determined by immunohistochemistry.
mRNA expression levels are indicated as Log2 transformed norma-
lized expression ratios as described previously.26
Table 1. Tumour cell characteristics
Characteristic
TRAF2 immunohistochemistry
Negative
(n = 33)
Positive
(n = 11) P-value
GCB ⁄ ABC microarray*
GCB 12 1 0.03
ABC 11 9
bcl-2†
+ 17 8 0.4
) 12 2
FLIP†
+ 8 6 0.3
) 18 5
XIAP†
+ 8 5 0.4
) 19 5
GrB mean‡ 16% 28% 0.04
*GCB ⁄ ABC proﬁle was determined only in those cases for
which a microarray was performed and not in the additional
eight cases.
†Missing numbers due to uninterpretable results of bcl-2,
FLIP and XIAP are not included.
‡Mean percentage of granzyme B-positive inﬁltrating cyto-
toxic T lymphocytes.
GCB, Germinal centre B-lymphocyte; ACB, activated B-cell;
TRAF2, tumour necrosis factor (TNF)-receptor associated
factor 2.
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progression-free survival time, the latter was there even
when analysis was restricted to ABC-like DLBCL. Thus,
expression of TRAF2 occurs mainly in cases with a
poor prognosis and provides additional prognostic
information in the group of ABC-like DLBCL.
ABC-like DLBCLs are characterized by constitutive
activation of the NF-jB pathway.30 This constitutive
NF-jB activation might be mediated via the adaptor
protein TRAF2 following triggering of various mem-
bers of the TNFR superfamily (e.g. CD30, CD40,
TNF-R2).14,16,17,20 Expression of TRAF2 was almost
exclusively observed in a proportion of ABC-like DLBCL,
suggesting that TRAF2 is indeed involved in NF-jB
activation in a subset of ABC-like DLBCLs with a
particularly poor prognosis. However, expression of
TRAF2 was not observed in all cases of ABC-like
DLBCL, indicating that other TRAF2-independent
NF-jB-activating mechanisms are involved in poor
prognosis in these cases.
The particularly poor prognosis in TRAF2+ ABC-like
DLBCL cases when compared with TRAF2) ABC-like
cases suggests that NF-jB activation itself is only part
of the explanation as to why clinical outcome is
relatively poor in ABC-like DLBCL. The additional effect
of TRAF2 expression may be explained by several
possible mechanisms.
Increased TRAF2 expression may result in inhibition
of chemotherapy-induced activation of the ER stress
response. TRAF2 binds to IRE1 and prevents the
dimerization and subsequent cleavage of caspase 12,
resulting in inhibition of apoptosis.22 Upon triggering
of IRE1, TRAF2 is also capable of activating NF-jB with
subsequent induction of expression of apoptosis inhib-
itory genes.19,23,31 Furthermore, the pro-apoptotic
factors BAX and BAK have previously been shown to
be associated with IRE1 and are crucial for IRE1
signalling upon ER stress.32 Disruption of this associ-
ation by binding of TRAF2 to IRE1 may be another
mechanism by which TRAF2 can inhibit apoptosis
induction following ER stress.31 Thus, expression and
binding of TRAF2 to IRE1 results in direct inhibition of
the ER pathway and in inhibition of the intrinsic
pathway via activation of the NF-jB pathway. Because
chemotherapeutic agents used in the treatment of
Figure 3. Kaplan–Meier analysis of the effects of TNFR-associated
factor (TRAF) 2 expression in diffuse large B-cell lymphoma (DLBCL).
Kaplan–Meier curves demonstrating differences in progression-free
and overall survival time between TRAF2+ versus TRAF2) cases.
A, Progression-free survival time for all tested cases. B, Overall
survival time for all tested cases. C, Progression-free survival time for
only activated B-cell-like DLBCL as determined by microarray
expression proﬁling.26
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DLBCL may also cause cell death by inducing ER
stress,31,33,34 inhibition of ER stress-mediated apoptosis
by TRAF2 may explain the observed poor clinical
outcome in TRAF2+ cases.
Another anti-apoptotic mechanism involving TRAF2
results in inhibition of the extrinsic apoptosis path-
way. Apoptosis induction via the extrinsic pathway is
initiated by signalling through death domain (DD)-
containing receptors of the TNFR superfamily. After
binding of Fas-associated death domain to the DD and
subsequent binding and cleavage of caspase 8 in the
DISC complex, effector caspases are cleaved, resulting
in induction of apoptosis.35 TRAF2 expression inter-
feres with this pathway through inhibition of cleavage
of caspase 8 in the DISC complex, in cooperation with
TRAF1, cIAP1 and cIAP2.17,18,36
We conclude that TRAF2 is expressed in a propor-
tion of ABC-like DLBCLs and usually not in GCB-like
DLBCL and that TRAF2 expression adds prognostic
value to GCB- versus ABC-like proﬁling. Further studies
are indicated to investigate whether TRAF2 expression
is also associated with poor outcome in rituximab
(R)-CHOP-treated DLBCL patients and whether the ER
pathway is indeed involved in resistance to chemo-
therapy. However, our data suggest that TRAF2 is
involved in activation of the NF-jB pathway in some
ABC-like DLBCLs and that expression of TRAF2 results
in particularly chemotherapy-resistant lymphoma
cells. Because of its possible strong effect on chemo-
therapeutic resistance, TRAF2 might be an attractive
candidate as a molecular target in TRAF2+ DLBCL.
References
1. The Non-Hodgkin’s Lymphoma Classiﬁcation Project. A clinical
evaluation of the International Lymphoma Study Group classi-
ﬁcation of non-Hodgkin’s lymphoma. Blood 1997; 89; 3909–
3918.
2. Coifﬁer B. Monoclonal antibody as therapy for malignant
lymphomas. C. R. Biol. 2006; 329; 241–254.
3. Johnstone RW, Rueﬂi AA, Lowe SW. Apoptosis: a link between
cancer genetics and chemotherapy. Cell 2002; 108; 153–164.
4. Kitada S, Pedersen IM, Schimmer AD et al. Dysregulation of
apoptosis genes in hematopoietic malignancies. Oncogene 2002;
21; 3459–3474.
5. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse
large B-cell lymphoma identiﬁed by gene expression proﬁling.
Nature 2000; 403; 503–511.
6. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell
lymphoma outcome prediction by gene-expression proﬁling and
supervised machine learning. Nat. Med. 2002; 8; 68–74.
7. Robertson JD, Gogvadze V, Zhivotovsky B et al. Distinct pathways
for stimulation of cytochrome c release by etoposide. J. Biol.
Chem. 2000; 275; 32438–32443.
8. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase
9-dependent apoptosis in 9L tumor cells. Mol. Pharmacol. 2001;
60; 1268–1279.
9. Gamen S, Anel A, Perez-Galan P et al. Doxorubicin treatment
activates a Z-VAD-sensitive caspase, which causes deltapsim loss,
caspase-9 activity, and apoptosis in Jurkat cells. Exp. Cell Res.
2000; 258; 223–235.
Table 2. Patient characteristics in relation to percentages of
TRAF2+ tumour cells
Characteristic
TRAF2 immunohistochemistry
Negative
(n = 33)
Positive
(n = 11) P-value*
Mean age, years
(range)
60.7 (15–83) 66.1 (43–94) NS
Sex
M 20 6 NS
F 13 5
Stage
1 + 2 17 2 NS
3 + 4 16 9
B symptoms
Yes 10 3 NS
No 23 7
International Prognostic Index
1 11 3 0.009
2 12 0
3 4 6
4 6 1
Complete remission
Yes 24 5 NS
No 9 5
Relapse
Yes 19 10 0.006
No 14 1
Death
Yes 13 7 NS
No 17 4
*Pearson chi-square test or Fisher’s exact test were used to
analyse qualitative variables, P-value < 0.05 was considered
signiﬁcant.
From one TRAF2+ case, not all clinical parameters could be
retrieved. Three TRAF2) cases died due to causes other than
lymphoma.
TRAF2, Tumour necrosis factor (TNF)-receptor associated
factor 2.
72
10. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by
caspase-3-dependent and -independent pathways in cisplatin-
resistant and -sensitive human ovarian cancer cell lines. Cancer
Res. 1999; 59; 3077–3083.
11. Karin M, Lin A. NF-kappaB at the crossroads of life and death.
Nat. Immunol. 2002; 3; 221–227.
12. Gilmore TD. Introduction to NF-kappaB: players, pathways,
perspectives. Oncogene 2006; 25; 6680–6684.
13. Barkett M, Gilmore TD. Control of apoptosis by Rel ⁄ NF-kappaB
transcription factors. Oncogene 1999; 18; 6910–6924.
14. Dempsey PW, Doyle SE, He JQ et al. The signaling adaptors and
pathways activated by TNF superfamily. Cytokine Growth Factor
Rev. 2003; 14; 193–209.
15. Muris JJ, Cillessen SA, Vos W et al. Immunohistochemical
proﬁling of caspase signaling pathways predicts clinical response
to chemotherapy in primary nodal diffuse large B-cell lympho-
mas. Blood 2005; 105; 2916–2923.
16. Grech AP, Amesbury M, Chan T et al. TRAF2 differentially
regulates the canonical and noncanonical pathways of
NF-kappaB activation in mature B cells. Immunity 2004; 21;
629–642.
17. Chung JY, Park YC, Ye H et al. All TRAFs are not created equal:
common and distinct molecular mechanisms of TRAF-mediated
signal transduction. J. Cell Sci. 2002; 115; 679–688.
18. Wajant H, Pﬁzenmaier K, Scheurich P. Tumor necrosis factor
signaling. Cell Death Differ. 2003; 10; 45–65.
19. Mauro C, Crescenzi E, De Mattia R et al. Central role of the
scaffold protein tumor necrosis factor receptor-associated factor 2
in regulating endoplasmic reticulum stress-induced apoptosis.
J. Biol. Chem. 2006; 281; 2631–2638.
20. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated
factors (TRAFs). Oncogene 2001; 20; 6482–6491.
21. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell
life and death decisions. J. Clin. Invest. 2005; 115; 2656–
2664.
22. Yoneda T, Imaizumi K, Oono K et al. Activation of caspase-12, an
endoplastic reticulum (ER) resident caspase, through tumor
necrosis factor receptor-associated factor 2-dependent mecha-
nism in response to the ER stress. J. Biol. Chem. 2001; 276;
13935–13940.
23. Kaneko M, Niinuma Y, Nomura Y. Activation signal of nuclear
factor-kappa B in response to endoplasmic reticulum stress is
transduced via IRE1 and tumor necrosis factor receptor-associ-
ated factor 2. Biol. Pharm. Bull. 2003; 26; 931–935.
24. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health
Organization classiﬁcation of tumours. Pathology and genetics
of tumours of hematopoietic and lymphoid tissues. Lyon: IARC
Press, 2001.
25. Muris JJ, Meijer CJ, Cillessen SA et al. Prognostic signiﬁcance of
activated cytotoxic T-lymphocytes in primary nodal diffuse large
B-cell lymphomas. Leukemia 2004; 18; 589–596.
26. Muris JJ, Ylstra B, Cillessen SA et al. Proﬁling of apoptosis genes
allows for clinical stratiﬁcation of primary nodal diffuse large
B-cell lymphomas. Br. J. Haematol. 2007; 136; 38–47.
27. Wright G, Tan B, Rosenwald A et al. A gene expression-based
method to diagnose clinically distinct subgroups of diffuse large B
cell lymphoma. Proc. Natl Acad. Sci. USA 2003; 100; 9991–
9996.
28. Hans CP, Weisenburger DD, Greiner TC et al. Conﬁrmation of the
molecular classiﬁcation of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood 2004;
103; 275–282.
29. Zapata JM, Krajewska M, Krajewski S et al. TNFR-associated
factor family protein expression in normal tissues and lymphoid
malignancies. J. Immunol. 2000; 165; 5084–5096.
30. Davis RE, Brown KD, Siebenlist U et al. Constitutive nuclear
factor kappaB activity is required for survival of activated B cell-
like diffuse large B cell lymphoma cells. J. Exp. Med. 2001; 194;
1861–1874.
31. Hu P, Han Z, Couvillon AD et al. Autocrine tumor necrosis factor
alpha links endoplasmic reticulum stress to the membrane death
receptor pathway through IRE1alpha-mediated NF-kappaB acti-
vation and down-regulation of TRAF2 expression.Mol. Cell. Biol.
2006; 26; 3071–3084.
32. Hetz C, Bernasconi P, Fisher J et al. Proapoptotic BAX and BAK
modulate the unfolded protein response by a direct interaction
with IRE1alpha. Science 2006; 312; 572–576.
33. Linder S, Shoshan MC. Lysosomes and endoplasmic reticulum:
targets for improved, selective anticancer therapy. Drug Resist.
Updat. 2005; 8; 199–204.
34. Jang YM, Kendaiah S, Drew B et al. Doxorubicin treatment in vivo
activates caspase-12 mediated cardiac apoptosis in both male
and female rats. FEBS Lett. 2004; 577; 483–490.
35. Ozoren N, El-Deiry WS. Cell surface death receptor signaling in
normal and cancer cells. Semin. Cancer Biol. 2003; 13; 135–147.
36. Wajant H, Scheurich P. Tumor necrosis factor receptor-associ-
ated factor (TRAF) 2 and its role in TNF signaling. Int. J. Biochem.
Cell Biol. 2001; 33; 19–32.
73
74
 
 
 
 
 
 
 
 
Chapter 6 
 
 
Profiling of apoptosis genes identifies distinct types of primary 
cutaneous large B-cell lymphoma 
 
 
Van Galen, Hoefnagel, Vermeer, Willemze, Dijkman, Tensen, De Boer, Meijer, Oudejans. 
J Pathol. 2008 Apr 26. [Epub ahead of print] 

Proﬁling of apoptosis genes identiﬁes distinct types
of primary cutaneous large B cell lymphoma
JC van Galen,1 JJ Hoefnagel,2 MH Vermeer,2 R Willemze,2 R Dijkman,2 CP Tensen,2 WPH de Boer,3 CJ Meijer1
and JJ Oudejans1*
1Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands
2Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands
3Department of Medical Oncology, VU University Medical Centre, Amsterdam, The Netherlands
*Correspondence to:
CJ Meijer, Department of Clinical
Pathology, VU Medical Centre,
De Boelelaan 1117, 1007 MB
Amsterdam, The Netherlands.
E-mail: cj.meijer@vumc.nl
No conﬂicts of interest were
declared.
Received: 25 September 2007
Revised: 10 April 2008
Accepted: 15 April 2008
Abstract
Two distinct primary cutaneous large B cell lymphomas are recognized: primary cutaneous
follicle centre lymphoma (PCFCL), characterized by an excellent prognosis, and primary
cutaneous large B cell lymphoma, leg-type (PCLBCL leg-type), with an unfavourable
prognosis. To determine whether inhibition of the apoptosis pathways may underlie the
difference in clinical outcome between PCFCL and PCLBCL leg-type, we investigated the
expression of only apoptosis-related genes by microarray expression proﬁling. Unsupervised
cluster analysis was carried out using 169 genes involved in apoptosis on a group of 21
previously untreated patients diagnosed with primary cutaneous large B cell lymphoma.
Cluster analysis resulted in two separate groups which showed large overlap with the
PCFCL and PCLBCL leg-type. One group was characterized by high expression levels of
pro- and anti-apoptotic genes. The other group was characterized by high expression levels
of apoptosis-inducing cytotoxic effector genes, possibly reﬂecting a cellular cytotoxic immune
response. Our results suggest that the clinically favourable PCFCLs are characterized by
a relatively intense cellular cytotoxic immune response and that PCLBCL leg-types are
characterized by constitutive activation of the intrinsic mediated apoptosis pathway, with
concomitant downstream inhibition of this apoptosis pathway. Thus, strategies neutralizing
the function of apoptosis-inhibiting proteins might be effective in PCLBCL leg-type.
Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Primary cutaneous B cell lymphomas [1] are a group
of B cell malignancies that arise in the skin and present
without evidence of extracutaneous involvement. A
signiﬁcant proportion of these primary cutaneous B
cell lymphomas are diffuse large B cell lymphomas
(DLBCL). In the new consensus WHO–EORTC clas-
siﬁcation for primary cutaneous lymphomas, two
distinct primary cutaneous large B cell lymphomas
(PCLBCLs) are distinguished; primary cutaneous folli-
cle centre cell lymphoma (PCFCL), with tumours pref-
erentially localized on trunk and scalp, and primary
cutaneous large B cell lymphoma, leg-type (PCLBCL
leg-type), with tumour localization mostly restricted
to the legs. Recent studies demonstrated that patients
with PCLBCL leg-type differ from PCFCL by a higher
age of onset, more frequent dissemination to extracu-
taneous sites and a poorer prognosis.
Patients presenting with PCLBCL leg-type have a
signiﬁcantly poorer prognosis than those with PCFCL,
with 5-year survival of approximately 50% and >95%,
respectively [1,2]. PCLBCL leg-type patients are
therefore treated with aggressive systemic (R-)CHOP
chemotherapy, while PCFCL patients receive local
radiotherapy [1]. The mechanism behind the difference
in prognosis is unclear. Previously, we have shown
that proﬁling of apoptosis genes in nodal DLBCL
stratiﬁes patients in groups with favourable versus
unfavourable clinical outcome [3]. In PCLBCL it is
well established that BCL2 protein is almost exclu-
sively expressed by the group with a poor progno-
sis, the PCLBCL leg-type group [4]. However, it
is unknown whether other anti-apoptotic genes are
also implicated in the pathogenesis and biological
behaviour of both types of PCLBCL.
At present three major apoptosis pathways are
recognized; an intrinsic, caspase 9-mediated path-
way, which is preferentially involved in chemotherapy
induced cell death [5], an extrinsic, caspase 8-mediated
pathway, which is activated by triggering of so-called
death receptors [6], and a third pathway that is induced
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by endoplasmic stress, resulting in the induction of
radical oxygen species, caspase 12 cleavage and apop-
tosis [7].
We recently demonstrated by genome-wide microar-
ray expression analysis that, also at the molecular
level, PCFCL and PCLBLC leg-type appear to be
distinct entities. PCLBCL leg-type cases are compa-
rable to activated B cell (ABC)-like DLBCL, while
gene expression patterns of PCFCL were more simi-
lar to germinal centre B cell (GCB) like DLBCL. [8]
In nodal DLBCL an ABC-like phenotype is associ-
ated with constitutive activation of the NFκB pathway,
resulting in up-regulation of many genes including
apoptosis-inhibiting genes, which may explain the rel-
atively poor outcome in ABC-like cases [5,9]. This
led to the hypothesis that in DLBCL intrinsic cellu-
lar resistance to chemotherapy and eventual clinical
outcome would depend on the balance between all
apoptosis-regulating genes [3]. To test this hypothe-
sis in PCLBCL, we investigated whether microarray
expression proﬁling of only apoptosis-related genes in
pre-treatment biopsies accurately distinguishes PCFCL
from PCLBCL leg-type, whether clustering based on
apoptosis proﬁles correlates with clusters obtained by
GCB versus ABC-like proﬁling, and whether apopto-
sis proﬁling has predictive value in PCLBCL leg-type
cases.
Materials and methods
Lymphoma samples
Pretreatment skin biopsies from eight patients with
PCFCL and 13 patients with PCLBCL leg-type were
included in this study. Only cases in which neo-
plastic B cells constituted 80% or more of the total
number of cells were selected. The diagnosis PCFCL
or PCLBCL leg-type was based on the criteria of
the WHO–EORTC classiﬁcation. [1] No evidence
of extracutaneous disease was present in any of the
patients at the time of diagnosis, as assessed by ade-
quate staging procedures, including physical examina-
tion, complete blood cell counts, computed tomogra-
phy of chest and abdomen and bone marrow biopsy
(see Table 1). This study was performed in accordance
with the Dutch ethical code and Leiden University
Medical Centre guidelines on surplus tissues.
Microarray procedures
Samples and microarrays were processed accord-
ing to the manufacturer’s protocol (available from
Affymetrix, Santa Clara, CA, USA). In brief, on
average 20–60 μg RNA was isolated from 50 ×
20 μm frozen sections, using the RNeasy-kit (Qiagen,
Hilden, Germany). Using the MessageAmp aRNA
Table 1. Clinical characteristics of primary cutaneous large B cell lymphoma patients
Case
no.
Clinical
presentation Sex (age)
Initial
therapy
Result of
initial
therapy Relapse
Apoptosis
proﬁle
Follow–up
status
(months)
PCFCL
1 Multiple tumours on the scalp M (76) RT CR None CCR D− (36)
2 Localized tumours on the chest M (38) RT CR None CCR A− (192)
3 Localized plaques and tumours on the back M (62) RT CR Skin + EC CCR D− (41)
4 Grouped plaques and tumours on the scalp M (61) RT CR Skin CCR A− (109)
5 Solitary tumour on the scalp F (69) RT CR None CCR A− (127)
6 Solitary tumour on the scalp M (37) RT CR Skin CCR A− (68)
7 Grouped plaques and tumours on the chest F (50) RT CR None CCR A− (24)
8 Solitary tumour on the scalp M (55) RT CR None CCR A− (8)
PCLBCL leg-type
9 Tumours on right cheek and right upper leg M (69) CHOP CR Skin + EC AAC D+ (35)
10 Three tumours on left lower leg M (47) CHOP CR None AAC A− (32)
11 Multiple tumours on right lower leg F (84) CHOP CR Skin AAC A− (30)
12 Two tumours on left lower leg F (74) CHOP CR None CCR A− (30)
13 Solitary tumour on lower leg F (62) RT CR None AAC D− (36)
14 Multiple tumours on left lower leg M (89) CHOP CR Skin + EC AAC D+ (12)
15 Multiple tumours on left lower leg F (90) PUVA-phototherapy∗ PR Skin + EC AAC D+ (29)
16 Solitary tumour on left lower leg F (88) RT CR Skin + EC AAC D+ (26)
17 Tumours and plaque on right lower leg F (77) RT CR Skin AAC A− (45)
18 Solitary tumour on left lower leg F (83) RT CR EC AAC D+ (24)
19 Multiple tumours on both legs F (76) CHOP CR Skin AAC D+ (11)
20 Multiple tumours on both lower legs F (75) CHOP CR None CCR A− (12)
21 Solitary tumour on right lower leg F (75) RT CR Skin + EC AAC D+ (73)
PCFCL indicates primary cutaneous follicle centre cell lymphoma; PCLBCL leg-type, primary cutaneous large B cell lymphoma of the leg; CHOP,
multi-agent anthracycline-based chemotherapy; RT, radiotherapy; CR, complete remission; PR, partial remission; EC, extra-cutaneous relapse;
CCR, cellular cytotoxic response; AAC, activated apoptosis cascade; A−, alive with no evidence of disease; A+, alive with disease; D+, died of
lymphoma; D−, died of other cause.
PCLBCL leg-type cases depicted in bold cluster in an unsupervised clustering analysis using only the expression proﬁles of apoptosis-regulating
genes with the PCFCL, rather than the other PCLBCL leg-type cases.
∗ Prior to admission, patient 15 had been treated with PUVA-phototherapy, resulting in partial remission.
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kit (Ambion, Huntingdon, UK), total RNA was
reverse-transcribed using an oligo(dT)-T7 promoter
primer to prime ﬁrst-strand synthesis. After second-
strand synthesis, the puriﬁed cDNA product was
in vitro transcribed using T7 RNA polymerase, biotin-
UTP (biotin-5′-triphosphate) and biotin-CTP (cyti-
dine triphosphate) to generate fragmented biotinylated
aRNA. Fragmented aRNA (15 μg) was hybridized to
a Human Genome U95Av2 Array (Affymetrix), inter-
rogating 12 625 human transcripts for 16 h at 45 ◦C
with constant rotation at 60 r.p.m. After hybridization,
the microarray was washed, stained on an Affymetrix
ﬂuidics station, and scanned with an argon-ion confo-
cal laser at 488 nm excitation and 570 nm detection
wavelengths.
Data acquisition and hierarchical cluster analysis
For each microarray, the spot intensities were Z score-
normalized [10] so as to achieve data standardization
across the lymphoma samples. Thus, for each microar-
ray, Z scores were computed according to the for-
mula: Z score = [2log(intensity) − μ]/σ , where μ is
the mean and σ the standard deviation of all log2-
transformed spot intensities of the microarray. Next,
the resulting Z score distributions for each sample
were conﬁrmed to be indeed standard normal, using
the Kolmogorov–Smirnov test [11]. The resulting
dataset contained expression ratios of 12 625 genes.
Hierarchical clustering analysis was performed using
TIGR TMEV 3.1 software (http://www.tm4.org/mev.
html) [12], using the algorithm initially developed by
Eisen et al [13]. All analyses were performed using
complete linkage analysis, using Pearson’s correlation,
according to the analytical procedures indicated by
Quackenbush [14].
Selection of apoptosis-related genes
Putative apoptosis-inducing, regulating and executing
genes for cluster analysis were selected from the NCBI
Entrez Gene database (http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?CMD=search&DB=gene; accessed
August 2005), using the keywords ‘apoptosis’ and
‘programmed cell death’ in the ‘gene ontology’ ﬁelds.
Of the resulting 374 genes, 169 were present on
our microarray platform, representing 1.3% of all the
genes present in the dataset.
Immunohistochemical validation
Expression of BIM, BAK1 and MCL1 was inves-
tigated at protein level in selected cases for which
parafﬁn-embedded material was available (n = 3 for
each group). Sections (3 μm) from parafﬁn-embedded
biopsy specimens were stained with the following anti-
bodies: BIM (Neomarkers, Lab Vision Corporation,
Fremont, CA, USA); BAK1 (Cell Signaling Technol-
ogy, Boston, MA, USA); and MCL1 (Dako, Glostrup,
Denmark). The antibodies were incubated overnight,
diluted 1 : 200 in PBS containing 1% BSA. A standard
highly-sensitive EnVision horseradish peroxidase sys-
tem (Dako, Glostrup, Denmark) was used. Antibodies
were visualized with the chromogen diaminobenzidine
(DAB).
Statistical analysis
Survival time was measured from time of initial diag-
nosis until death with disease or until end of follow-up.
Patients who died of causes unrelated to the disease
were censored at the time of death. Survival curves
were constructed with the Kaplan–Meier method. Dif-
ferences between the curves were analysed using the
Log-rank test. All p values were based on two-tailed
statistical analysis, considering p < 0.05 as signiﬁcant.
Analyses were performed using SPSS statistical soft-
ware (version 11.5, SPSS Inc, Chicago, IL, USA).
Results
Apoptosis proﬁling results in two groups largely
overlapping with PCFCL and PCLBCL, leg-type
Unsupervised hierarchical cluster analysis of 21 PCB-
CLs using only apoptosis-related genes resulted in
two groups of lymphomas (Figure 1). These groups
showed great overlap with PCFCL and PCLBCL leg-
type entities: only two PCLBCL leg-type cases were
classiﬁed in the same group as the PCFCL cases.
Expression proﬁles of these two groups showed strong
similarities with two of the three previously identiﬁed
nodal DLBCL groups resembling AAC and CCR type
DLBCL.
Activated apoptosis cascade (AAC) type
This group (depicted in red, n = 11) was characterized
by high expression levels of many pro-apoptotic genes,
in particular, genes involved in the caspase 9-mediated
pathway, including BAX, BIM (BCL2L11 ), PUMA
(BBC3 ) and AIF (PDCD8 ), and many anti-apoptotic
genes, including BAG1, BCL2L1 (BCLXL), BCL2,
BIRC1 and TRAF2. Immunohistochemical analysis
conﬁrmed that protein expression of BIM and BAK1
genes is indeed present in neoplastic cells of these
cases (Figure 2a, b, respectively). All 11 AAC-type
lymphomas were previously classiﬁed as PCLBCL
leg-type with an ABC-like phenotype (Table 1).
Cellular cytotoxic response (CCR) type
This group (depicted in blue, n = 10) is character-
ized by high expression levels of apoptosis-inducing
immune effector molecules, including granzyme A,
granzyme K, granzyme M, TRAIL/Apo2L (TNFSF10 ),
and pro-inﬂammatory genes such as Caspase 1, Cas-
pase 4 and NALP and, to a lesser extent, also by anti-
apoptotic genes including XIAP and MCL1. Immuno-
histochemical staining conﬁrmed protein expression
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Figure 1. Hierarchical cluster analysis of PCLBCL for 169 apoptosis genes resulting in two groups with distinct expression proﬁles
of apoptosis-regulating genes. The upper box (red-marked area) indicates the genes with relatively high expression levels in the
AAC group. The lower box (blue-marked area) indicates the genes with relatively high expression levels in the CCR group. The
genes indicated in red were previously included in the AAC-type proﬁle in nodal DLBCL; those indicated in blue were previously
included in the CCR-type
Figure 2. (A, B) Immunohistochemical detection of pro-apoptotic genes BIM (BCL2L11) and BAK1 in AAC-type PCLBCL leg-type.
(C) Immunohistochemical detection of MCL1 in CCR-type PCFCL
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of MCL1 in neoplastic cells of CCR-type lymphoma
(Figure 2c). This group included all eight PCFCLs and
in addition two PCBCL leg-type cases.
Apoptosis proﬁling strongly correlates with clinical
outcome
The difference in clinical outcome between PCFCL
and PCLBCL leg-type is well established. Clinical
characteristics of the included cases are shown in
Table 1. PCLBCL leg-type cases with a AAC-type
proﬁle demonstrated a very poor clinical outcome,
while all PCFCLs and the two PCLBCL leg-type
patients with a CCR-type proﬁle demonstrated a highly
favourable clinical outcome (Figure 3, Table 2). Thus,
proﬁling based on apoptosis genes adequately strat-
iﬁes PCBCL in patients with favourable versus
unfavourable outcome, and identiﬁed two PCLBCL
leg-type cases with a favourable outcome (Figure 3).
Discussion
In the WHO–EORTC classiﬁcation of cutaneous lym-
phomas, two types of PCLBCLs are recognized:
PCFCL and PCLBCL leg-type [1]. The difference
between these types is based on clinical, histological,
immunophenotypical and genetic differences. Microar-
ray expression analysis indicated that PCFCL and
PCLBCL leg-type have expression proﬁles similar to
that of germinal centre B cell-like and activated B cell-
like DLBCL, respectively [8]. Previous studies demon-
strated that an ABC-like phenotype is characterized by
constitutive activation of the NFκB pathway, result-
ing in up-regulation of apoptosis-inhibiting genes. It
is thought that this NFκB-mediated up-regulation of
anti-apoptotic genes causes intrinsic cellular resistance
Table 2. Clinical characteristics of primary cutaneous large B
cell lymphoma patients presenting with either AAC or CCR
phenotype
Clinical
characteristics AAC CCR p Value
Mean age (range) 76 (47–90) 60 (37–76) ns
Gender
F 8 4 ns
M 3 6
CR
No 1 0 ns
Yes 10 10
Relapse
No 2 7 0.02
Yes 9 3
Death due to lymphoma
No 4 10 0.001
Yes 7 0
PCLBLC
PCFCL 0 8 < 0.001
PCLBCL leg-type 11 2
Phenotype
GCB 0 7 0.002
ABC 10∗ 3
∗ In one case no ABC/GCB proﬁle was determined.
CCR, cellular cytotoxic response; AAC, activated apoptosis cascade;
PCLBCL, primary cutaneous large B cell lymphoma; PCFCL, primary
cutaneous follicle centre lymphoma; PCLBCL leg-type, primary
cutaneous large B cell lymphoma; GCB, germinal centre B cell-like;
ABC, activated B cell-like.
to chemotherapy [9]. Whether such a mechanism is
also operational in PCLBCL leg-type and could play
a role in the poor prognosis of these lymphomas has
not been investigated thus far. If this is true, the intrin-
sic cellular resistance to chemotherapy and predicted
Figure 3. Overall survival time analysis for the two groups of PCLBCL resulting from unsupervised cluster analysis. Depicted are
the resulting Kaplan–Meier curves for all cases (left panel) and only the PCLBCL leg-type cases (right panel). Red line indicates
AAC-type cases; blue line indicates CCR-type cases
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clinical outcome would depend on the balance between
all apoptosis-regulating genes, as demonstrated previ-
ously for primary nodal DLBCL [3].
Indeed, unsupervised proﬁling of apoptosis-related
genes resulted in two groups with a high degree
of overlap with the PCFCL/PCLBCL leg-type enti-
ties. The group with an unfavourable outcome (all
PCLBCL leg-type) showed an expression proﬁle
highly comparable with the previously determined
AAC signature in nodal DLBCL. The other, clinically
favourable, group showed an expression proﬁle which
is very similar to the CCR signature in nodal DLBCL.
These CCR cases included all PCFCLs as well as two
PCLBCL leg-type cases with favourable outcome. In
contrast to our study in DLBCL, where three dis-
tinct groups were recognized, only two groups were
recognized within these PCLBCL cases. This is prob-
ably caused by the smaller size of the groups in this
study, resulting in a selection of patients — within the
PCLBCL cases with a CCR signature, several genes
were expressed which were not expressed in DLBCL
cases of the CCR phenotype.
Results from this study suggest that the poor out-
come in PCLBCL leg-type cases may result from high
expression levels of many anti-apoptotic genes, includ-
ing BCL2 (which is a well established marker for
PCLBCL leg-type cases) [4], but also other apoptosis-
inhibiting genes, such as BIRC1, BAG1 and TRAF2.
Similar to our ﬁndings in nodal DLBCL these cuta-
neous lymphomas are also characterized by high
expression levels of pro-apoptotic genes, including
BCL2L11 (BIM), BAK1, BBC3 (PUMA) and PDCD8
(AIF), suggesting constitutive activation of the intrin-
sic apoptosis pathway. We have recently shown in
isolated lymphoma cells that in AAC-type lymphomas
the intrinsic apoptosis pathway is indeed constitutively
activated, and that chemotherapy resistance is not
caused by failure to activate the intrinsic apoptosis cas-
cade but is caused by complete inhibition of the down-
stream convergence apoptosis pathway [15]. Thus,
neutralization of downstream apoptosis inhibitory pro-
teins using small antagonistic molecules might be a
very attractive alternative treatment option in these
chemotherapy-refractory PCLBCL leg-type cases [16].
Constitutive activation of the intrinsic apoptosis path-
way may be triggered by different upstream mech-
anisms. One of these is induction of apoptosis by
certain activated mitogenic oncogenes [17,18]. A pos-
sible candidate is E2F1, which was included in the
AAC gene signature and also in the nodal DLBCL
AAC signature and has a strong apoptosis-inducing
effect [17].
The other group (including all PCFCLs and two
PCLBCL leg-type cases) was characterized by high
expression levels of genes involved in a cytotoxic
immune response including granzymes, apoptosis-
inducing ligands TNFSF10 (TRAIL), TNFSF12
(TWEAK ) and TNFSF13 (APRIL), probably reﬂecting
the presence of an intense T cell-mediated immune
response. In cutaneous B cell lymphomas a rela-
tively strong cellular cytotoxic immune response was
thus associated with a favourable outcome, which
is in accordance with previous studies describing
favourable outcome in patients with high levels of
tumour-inﬁltrating T lymphocytes [19]. When com-
pared to the AAC-type lymphomas, these CCR-
type lymphomas expressed relatively low levels of
anti-apoptotic genes involved in the intrinsic apop-
tosis pathway. The PCFCL lymphomas are in all
cases treated only with radiotherapy (see Table 1).
Radiation-induced cell death involves activation of this
intrinsic apoptosis pathway [20,21] and thus the rel-
atively restricted expression of anti-apoptotic genes
may explain the favourable response to radiotherapy
and the eventual favourable outcome observed in these
cases.
We conclude that the clinically favourable PCF-
CLs are characterized by an apoptosis expression pro-
ﬁle probably reﬂecting a cellular cytotoxic immune
response, and that therapy-refractory PCLBCL leg-
type cases are characterized by an expression pro-
ﬁle probably reﬂecting constitutive activation of the
intrinsic mediated apoptosis pathway with concomi-
tant downstream inhibition of this apoptosis pathway.
Thus, strategies neutralizing the function of apoptosis-
inhibiting proteins might be effective as an alter-
native treatment modality in chemotherapy-refractory
PCLBCL.
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General discussion 
 
 
Lymphomas form a group of heterogeneous malignancies characterized by the 
uncontrolled growth of lymphocytes.1 Several pathways are important in development 
and maintenance of these malignant lesions. These processes involve the hallmarks 
of cancer, such as self-sufficiency in growth signals, irresponsiveness to anti-growth 
signals, limitless replicative potential and evasion of apoptosis.2 Disruptions of the 
apoptosis pathway determine the capacity of tumor cells to withstand therapy and 
thus determine prognosis in patients.3 In this thesis the focus lies on understanding 
disregulation of the mechanisms involved in regulation of apoptosis in B-cell 
lymphomas and how these disruptions may influence disease outcome. 
Primary nodal and cutaneous large B-cell lymphomas are heterogeneous lymphoma 
entities. Predicting prognosis remains difficult, although based on genome wide 
expression profiling  several groups have now been distinguished within large B-cell 
lymphomas with differential prognosis.4,5 Importantly, complete pathways involved in 
regulation of apoptosis can be recognized, thereby increasing our knowledge on 
development and chemotherapy resistance of lymphomas.6 This knowledge should 
eventually lead to individualized specific treatment strategies, improving disease 
outcome. 
 
In the first micro-array study performed on DLBCL4, BMI1 was among the genes 
identified as highly expressed in patients with poor outcome. BMI1 is part of the 
family of Polycomb genes which are primarily involved in the epigenetic regulation of 
gene expression.7,8 Recently other functions of Polycomb genes have been 
identified, including stem cell maintenance,  regulation of cell cycle, senescence and 
apoptosis9,10,11 
Prolonged co-expression of Polycomb proteins such as BMI1 and EZH2 in 
hematological malignancies appears to be aberrant.8 Relative high levels of co-
expressed  BMI1 and EZH2 are associated with aggressieve behavior in DLBCL12, 
and high BMI1 expression levels are correlated with poor prognosis. (chapter 4) 
Although in all cells of the germinal center components of both PRC1 and PRC2 
were found, co-expression of BMI1 and EZH2 in non-malignant tonsillar tissue was 
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only found in a small group of dividing cells in germinal center cells, this group 
probably is a transient population of cells. (chapter 2) This may imply that aberrant 
expression of Polycomb complexes as seen in various B-cell lymphomas (12,13 and 
chapter 3) and thus deregulation of the normal functions of Polycomb genes (such as 
epigenetic silencing) may be a factor involved in lymphoma genesis. 
As initially shown in mice, BMI1 negatively regulates p16INK4a/p14ARF expression 
in normal tissue, thereby interfering with cell cycle regulation and the capacity of a 
cell to undergo senescence.14 In HL and DLBCL, high BMI1 expression was not 
necessarily found to be correlated with low p16INK4a/p14ARF expression or vice 
versa. (chapter 3 and 4) This does not rule out that in HL and DLBCL BMI1 has an 
effect on p16INK4a/p14ARF expression, and thereby inhibition of cell death,. Other 
factors may also influence activity of the CDKN2A locus and thereby masking the 
effect BMI1. 
Via the CDKN2A locus BMI1 contributes to self-renewal and senescence in murine 
embryonic cells.15 In the germinal center BMI1 may have a similar function as 
germinal center cells and stem cells belong to an exclusive club of cells capable of 
self-renewal.16 Indeed, both in CD34+ hematopoietic stem cells from the bone 
marrow17 as well as in a small portion of the cycling cells of the germinal center 
(chapter 2) expression of BMI1 was observed. If self renewing cells are indeed 
characterized by co expression of BMI1 and markers for proliferation, this may 
implicate that BMI1 positive tumor cells are the cells which are responsible for 
maintenance and expansion of tumor load. 
In contrast to hematological malignancies, in solid tumors (mamma and prostate 
carcinomas) EZH2 expression levels were correlated to poor prognosis and degree 
of disease.18,19 This discrepancy could be explained by other factors involved in gene 
silencing in different types of tissue. This may interfere with Polycomb function and 
therefore the expression of a certain Polycomb gene may not have the same effect in 
every tissue type. Alternatively, the aberrant expression patterns of Polycomb genes 
may interfere with other processes rather than gene silencing: pathways involved in 
signal transduction or apoptosis/cell cycle regulation may be affected by the 
observed Polycomb expression patterns. Examples of this include the previously 
reported involvement of EZH1 in T-cell receptor signaling10 and EZH2 in integration 
of estrogen receptor and Wnt signaling pathways.20 Both mechanisms are involved in 
cell survival and cell cycle progression. 
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From the micro array study of DLBCL by our group5 it was found that high expression 
of apoptosis regulating factors is correlated with poor prognosis. Notably not only the 
expression of anti-apoptotic but also pro-apoptotic genes is elevated in cases with 
poor prognosis, indicating a downstream disruption of the apoptosis pathways 
involved in apoptosis induction by chemotherapeutics. In line with this study is our 
finding that expression of the anti-apoptotic factor TRAF2 is correlated with poor 
prognosis in DLBCL. (chapter 5) TRAF2 functions at the cell membrane where it 
prevents apoptosis induction of tumor cells by the immune system by recruitment of 
TRAF1 cIAP1 and cIAP2 to death receptors of the TNF receptor superfamily.21 
TRAF2 also is capable of inhibiting apoptosis caused by the unfolded protein 
response from the endoplasmic reticulum. This intracellular stress mechanism 
induces apoptosis via IRE mediated caspase 12 activation, TRAF2 binds the IRE 
receptor and prevents cleavage of procaspase 12 into its active form.22 TRAF2 can 
also induce the expression of various downstream inhibitors of apoptosis via the 
activation of NFB. The role of TRAF2 in NFB activation in DLBCL is hard to prove 
as in it is well known that the B-cell receptor pathway is constitutively activated in the 
tumor cells, resulting in activation of NFB.23 Thus, high expression of TRAF2 may 
be the cause of insensitivity of tumor cells to apoptosis induction by both infiltrating 
cytotoxic T-lymphocytes as well as chemotherapeutics. At first sight the cause of this 
likely lies in activation of NFB, resulting in expression of anti-apoptotic factors. 
However, not in all cases with activation of NFB TRAF2 is detectable and therefore 
one might question whether TRAF2 is important at all in NFB activation in DLBCL. 
Constitutive activation of (members of) the BCR pathway is much more likely to be 
responsible for NFB activation, as this mechanism has already been proposed 
previously.24,25,26 Since no other pathway has been described in DLBCL of being able 
to inhibit the response to endoplasmic stress, we would like to propose that TRAF2 
plays an important role in inhibition of the unfolded protein response in DLBCL cells 
and thereby in poor prognosis following chemotherapy. 
Concluding, TRAF2 is thought to be involved NFB activation in at least a part of the 
ABC like DLBCL cases studied. It is expected that the development of IB inhibiting 
drugs will improve disease outcome in these patients. Since TRAF2 is involved in 
several other processes involving inhibition of cell death27,28, merely inhibiting NFB 
activation may not be sufficient to completely abolish TRAF2’s negative effects. 
Selectively targeting TRAF2 via either a small molecule inhibitor or even RNAi might 
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be a viable strategy29 since it has been shown that other members of the TRAF 
family can take over TRAF2 functions in normal cells.27 
  
PCLBCL and DLBCL are related malignancies as both tumor types are large B-cell 
entities. The main difference between these lymphoma types is the location: primary 
nodal DLBCL arises in lymph nodes while PCLBCL arises in the skin. PCLBCL is 
separated in two entities based upon histology of the tumor cells and location of the 
primary tumor. Patients with PCLBCL, LT (tumor in most patients located on the leg) 
have poor prognosis while those with PCFCL (tumor in most patients on the scalp 
and trunk) have good prognosis.30,31 In primary nodal DLBCL two major groups can 
be distinguished based upon gene expression analysis: activated B-cell (ABC) like 
with a poor prognosis and germinal center B-cell (GCB) like DLBCL with better 
prognosis.4 Using micro-array analysis of PCLBCL cases it was determined that gene 
expression signature of PCLBCL, LT was similar to that of ABC-like DLBCL while 
PCFCL gene expression patterns were similar to GCB-like DLBCL.32 Thus not only 
clinical outcome but also gene expression patterns of these two groups of 
lymphomas were similar. 
Clustering in an unsupervised way using all genes available on the micro-array, nodal 
DLBCL yields a group of ABC-like and GCB-like DLBCL cases4, a third group of non-
ABC and non-GCB was identified in another clustering analysis.33 Since the 
expression of apoptosis regulating genes is thought to be important in resistance to 
chemotherapy, clustering has also been performed using only apoptosis regulating 
genes.5 This clustering method also yields 3 groups in primary nodal DLBCL with 
distinct differential survival. In PCLBCL disruption of genes involved in apoptosis 
regulation had already been correlated to prognosis: CDKN2A disruption by either 
deletion or hypermethylation of the locus as well as amplification of the BCL2 locus 
was found in the majority of PCLBCL, LT patients.34 Indeed we showed that 
clustering of PCLBCL using expression data of genes involved in induction and 
execution of apoptosis was able to segregate the cases into two groups with 
differential prognosis and greatly overlapping currently used stratification strategies, 
which are primarily based upon tumor location and (immuno-)histological properties 
of the tumor cells. Neutralizing the function of apoptosis-inhibiting proteins which are 
hyper-activated in PCLBCL, LT might be an effective future therapeutic strategy. 
(chapter 6)  
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New treatment strategies are currently being developed or evaluated in clinical 
settings to combat large B-cell lymphomas. With the advent of Rituximab 
supplemented CHOP therapy regimens (R-CHOP) in the treatment of DLBCL35 and 
PCLBCL36 it will be interesting to see which of the identified groups of patients will 
benefit most from this new treatment. 
 
Our observations on disruption of apoptotic pathways in lymphomagenesis may lead 
to even more promising treatment possibilities. Currently various specific small 
molecule antagonists of apoptosis regulators are being developed, while several are 
already undergoing clinical testing at this moment.37 Restoring apoptotic pathways by 
these antagonists may play an important role in future eradication of these 
malignancies. The development of inhibitors targeting various genes of the apoptosis 
cascade allows individual highly specific treatment schemes. In order for such 
treatments to be successful, it will be essential to know which apoptosis pathways 
are disrupted in individual patients. 
 
 
Figure 4. Overview of pathways involved in lymphomagenesis and/or poor response 
to therapy in DLBCL patients as discussed in this thesis. Indicated are the influences 
of over expression of BMI1 and TRAF2, while also the more general disruption of 
apoptotic pathways in PCLBCL is shown. All alterations identified cause reduced 
sensitivity to induction of apoptosis via the intrinsic, extrinsic and endoplasmic 
reticulum pathway. This results in increased resistance to cellular and drug-induced 
cytotoxicity.
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Lymfomen zijn tumoren die ontstaan uit cellen van het immuunsysteem. Er wordt 
doorgaans een onderscheid gemaakt tussen Hodgkin lymfomen (HL) en de vaker 
voorkomende Non-Hodgkin lymfomen (NHL).Over het algemeen hebben de NHL een 
slechtere prognose dan de HL. De groep van NHL is echter zeer heterogeen, zowel 
wat betreft geno- en fenotypische kenmerken als prognose. 
 
De prognose voor patiënten is afhankelijk van hoe tumorcellen reageren op de 
toegediende chemotherapeutica. Indien zelfs ook maar enkele tumorcellen in staat 
zijn om een behandeling met chemotherapeutica te overleven is dit zeer nadelig voor 
de patiënt. Tumorcellen kunnen diverse methodes aanwenden om chemotherapie te 
overleven. Sommige cellen hebben pompen in hun membraan die 
chemotherapeutica naar buiten kunnen pompen, hierdoor kan er geen schade 
aangericht worden in de cel. Indien de chemotherapeutica in de cel blijft en er wel 
schade aangericht wordt, treden er cellulaire mechanismen in werking waardoor de 
cel normaal gesproken zou moeten sterven, dit heet apoptose. Als een cel echter 
geen goed functionerende apoptose machinerie meer heeft zal de cel ook niet 
sterven als gevolg van de chemotherapeutica en zal de tumor voortwoekeren. 
 
Apoptose kan op meerdere manieren geïnduceerd worden en leidt tot de 
opeenvolgende activatie van een aantal caspases die de uiteindelijke celdood 
uitvoeren. Er kunnen drie pathways onderscheiden worden in apoptose inductie: de 
intrinsieke, de extrinsieke en de endoplasmatisch reticulum (ER) route. Deze 
pathways worden op verschillende wijze geactiveerd maar leiden uiteindelijk tot het in 
werking zetten van celdood via dezelfde effector caspases. 
 
De intrinsieke pathway wordt in gang gezet door intracellulaire veranderingen 
waardoor de membraan van het mitochondrium verstoord raakt en er factoren 
vrijkomen die samen het apoptosoom vormen. Dit apoptosoom bevat geactiveerd 
caspase 9 wat uiteindelijk caspase 3 activeerd en daardoor celdood induceerd. Bij de 
extrinsieke pathway wordt er een signaal van buitenaf via receptoren, die door de 
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membraan heen steken, naar binnen doorgegeven. Er wordt een complex van 
eiwitten gevormd rondom het intracellulaire gedeelte van de receptor waarbij 
geactiveerd caspase 8 op zijn beurt wederom caspase 3 aanzet tot het uitvoeren van 
executie. Ten slotte is er in de ER route sprake van defecte vorming van eiwitten 
waardoor allerlei processen in de cel verstoord zouden kunnen raken. Receptoren op 
het ER herkennen de verkeerd gevouwen eiwitten en via caspase 12 wordt ook in dit 
geval caspase 3 geactiveerd. 
 
De regulatie van deze routes is zeer complex. In de eerste plaats is de activatie van 
de caspases een opeenvolging van meerdere stappen waarbij van de inactieve 
caspases stukjes worden afgeknipt waardoor een werkzame variant overblijft. 
Bovendien zijn er op vele niveaus van activatie factoren aanwezig die de celdood 
stimuleren danwel remmen. Indien er een defect is in een factor die de celdood moet 
bevorderen, of als er te veel is van een factor die de celdood kan remmen, kan er 
een probleem ontstaan zodra deze cellen schade oplopen waardoor ze eigenlijk in 
apoptose zouden moeten gaan. Indien deze schade ongeremde groei van de cel 
veroorzaakt heeft het lichaam een nog veel groter probleem, aangezien deze cel tot 
een tumor uit zou kunnen groeien. 
 
In dit proefschrift zijn verschillende afwijkingen beschreven zoals die gevonden zijn in 
grootcellige B-cel lymfomen. We hebben geprobeerd om afwijkende 
expressiepatronen van apoptose regulerende eiwitten te correleren aan prognose 
van de patiënt. Verder proberen we aanbevelingen te doen over toekomstige 
behandelmethoden die de prognose zouden kunnen verbeteren. 
 
In hoofdstuk 2 wordt beschreven wat de expressiepatronen zijn van zogenaamde 
Polycomb eiwitten in de normale B-cel ontwikkeling. Het is al langer bekend dat deze 
Polycomb eiwitten heel belangrijk zijn voor het ontstaan van B-cellen en voor controle 
van celdeling. In eerdere studies was aangetoond dat Polycomb eiwitten in 2 
groepen uiteen vallen die ieder een complex kunnen vormen. Deze complexen 
zouden volgens deze eerdere studies niet samen tot expressie komen in gezonde B-
cellen maar wel in B-cel lymfomen. In onze studie laten we zien dat de 2 complexen 
wel degelijk samen tot expressie komen in gezonde B-cellen, maar de samenstelling 
kan zodanig veranderen dat sommige onderdelen van de complexen normaal 
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gesproken maar in een zeer klein aantal cellen samen aangetoond kan worden. De 
co-expressie van verschillende onderdelen van de complexen in Hodgkin’s lymfoom 
zoals beschreven in hoofdstuk 3 is dus niet geheel in strijd met de situatie zoals te 
zien in gezonde B-cellen. Het is echter wel ongebruikelijk dat zoveel cellen co-
expressie vertonen, aangezien in gezonde B-cellen dit slechts in een fractie van de 
cellen gezien wordt. Het is dus waarschijnlijk zo dat de expressie van de complexen 
normaal gesproken strak gereguleerd wordt en dat deze regulatie in lymfomen is 
weggevallen waardoor beide complexen in hun geheel grotendeels samen tot 
expressie komen. Dit heeft dan waarschijnlijk weer tot gevolg dat regulatie van 
celdeling en apoptose in deze cellen verstoord is. 
 
In hoofdstuk 4 laten we vervolgens zien dat verkeerde expressie van het Polycomb 
eiwit BMI1 ook daadwerkelijk leidt tot slechte prognose. In dit hoofdstuk proberen we 
een verklaring te vinden voor de slechte prognose aan de hand van een eerder 
gepubliceerd model waarin beschreven wordt dat p14ARF en p16INK4A expressie 
door BMI1 gereguleerd wordt. In onze groep lymfomen vinden we echter geen 
duidelijk verband tussen de expressie van BMI1 en die van p14ARF/p16INK4A. 
Waarschijnlijk zijn er dus ook andere factoren dan BMI1 betrokken bij de regulatie 
van p14ARF/p16INK4A, waardoor het effect van BMI1 gemaskeerd wordt. 
 
Vervolgens wordt in hoofdstuk 5 de expressie van TRAF2 in lymfomen beschreven. 
TRAF2 is een interessant eiwit aangezien het een belangrijke schakel vormt in de 
doorgifte van signalen van buiten naar binnenin de cel. Al veel langer werd 
verondersteld dat verhoogde expressie van TRAF2 zou kunnen leiden tot extra hoge 
productie van anti-apoptotische factoren en daardoor slechte prognose. Inderdaad 
vinden wij in onze groep lymfomen een associatie tussen verhoogde TRAF2 niveaus 
en verslechterde respons op chemotherapie. De slechte prognose als gevolg van 
verhoogde TRAF2 niveaus is op 2 manieren te verklaren. In de eerste plaats komt 
TRAF2 alleen maar hoog tot expressie in tumoren die gekenmerkt worden door hoge 
expressie van anti-apoptotische factoren. Of dit veroorzaakt wordt door TRAF2 is 
echter niet duidelijk aangezien niet alle lymfomen uit deze groep hoge TRAF2 
expressie kennen. Verder is het zo dat ook TRAF2 directe anti-apoptotische 
kenmerken heeft aangezien het de caspase 8 gemedieerde extrinsieke route kan 
remmen. Ook is TRAF2 betrokken bij de respons op intrinsieke celstress waarbij 
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eiwitten verkeerd gevouwen worden. Normaal gesproken zou een cel dan na 
caspase 12 activatie in apoptose gaan, TRAF2 kan echter ook dit proces remmen. Al 
met al zou TRAF2 op vele vlakken actief kunnen zijn in het veroorzaken van tumor-
groei. Remming van TRAF2 zou mogelijk positieve gevolgen kunnen hebben op 
overleving van de patiënten. 
 
In hoofdstuk 6 hebben we met behulp van een micro-array gekeken naar de hoogte 
van expressie van alle genen die betrokken zijn bij apoptose regulatie in 2 zeldzame 
groepen lymfomen. De PCLBCL, LT en PCFCL zijn beide grootcellige B-cel 
lymfomen maar komen in tegenstelling tot de meeste vormen van lymfomen niet in 
de lymfklier maar in de huid voor. Al eerder was een studie uitgevoerd waarbij op 
basis van expressie van apoptose regulerende genen 3 verschillende groepen 
konden worden onderscheiden in lymfomen uit de lymfklier. Met een zelfde techniek 
konden we ook PCLBCL, LT en PCFCL van elkaar onderscheiden. De waarde van 
deze bevinding ligt in het feit dat er op dit moment specifieke apoptose inducerende 
medicijnen worden ontwikkeld tegen de lymfklier lymfomen. Doordat we nu met 
behulp van de micro-array hebben aangetoond dat waarschijnljik soortgelijke 
mechanismen verantwoordelijk zijn voor slechte prognose in deze huidlymfomen, 
kunnen de ontwikkelde medicijnen ook gebruikt worden voor de behandeling van 
deze zeldzame gevallen. 
 
Concluderend: het is duidelijk dat er in de onderzochte groepen lymfomen 
afwijkingen zijn in de expressie van apoptose regulerende genen. Door het 
ontwikkelen van medicijnen die kunnen inwerken op de betrokken mechanismen 
zouden we in staat moeten kunnen zijn om zeer selectief apoptose programma’s aan 
te zetten. In combinatie met de huidige chemotherapeutische protocollen zouden we 
dan in staat kunnen zijn om de prognose van de patiënten te verbeteren. 
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Tonia en Carla wil ik bedanken voor de vele pogingen gaatjes te vinden in de agenda 
van Chris, de opbeurende praatjes en de broodnodige kannen koffie. 
 
De fotografen Jaap en Ron bedankt voor alle last-minute klussen en adviezen hoe 
mijn figuren nog mooier konden worden. 
 
De mensen van de immuno en histo met Thea en Mohammad aan het hoofd wil ik 
bedanken voor het delen van kennis, ervaring en een paar kostbare vierkante 
metertjes labruimte. 
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Uiteraard wil ik mijn nieuwe werkomgeving niet vergeten. Bedankt Peter en Frank dat 
jullie mij deze kans hebben gegeven, ondanks dat ik nog niet klaar was. Vanaf nu is 
het alleen nog leukemie wat mijn aandacht heeft. En Jeroen, BTG1 is toch echt het 
allerbelangrijkste eiwit ter wereld! De rest van het lab bedankt voor het regelmatig 
informeren naar de vorderingen, het is nu echt af dus ben ik nu dan eindelijk wel een 
echte postdoc??? 
 
Gelukkig was er buiten het lab ook een leven en ik wil de vriendengroep, waaronder 
mijn broer Bas, bedanken voor het broodnodige vertier buiten werktijd. Af en toe 
probeerde ik wel wat te vertellen over mijn onderzoek maar dat was uiteraard 
vergeefse moeite. Een medisch bioloog moet ook gewoon begrijpen dat verhaaltjes 
over DNA, cellen en eiwitten wel grappig zijn, maar er zijn toch echt belangrijkere 
zaken op de wereld! Mannen, bedankt voor de steun, gezelligheid, kroegentochten 
en niet te vergeten het wekelijkse zwemmen. 
 
Joop en Corry, dankzij jullie liefde en geduld ben ik, geloof ik, toch nog aardig op mijn 
pootjes terecht gekomen. Nu de promotie achter de rug is zal ik eindelijk weer wat 
meer tijd hebben om bij jullie langs te komen. Oei, is dat een belofte die schuld 
maakt? 
 
Lieve Manon, toen wij elkaar leerden kennen was ik net bezig met het afronden van 
mijn studie en je hebt dan ook de hele promotie van A to Z meegemaakt Door alle 
promotie-perikelen heen heb jij me altijd weten te steunen en nu jouw studie ook 
tegen z’n eind loopt is er tijd om wat meer leuke dingen te gaan doen. Zullen we 
beginnen met de westkust? 
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